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Investigation of synthetic hydrogels as therapy for myocardial infarction 
 
This thesis investigated the potential of synthetic polyethylene glycol (PEG) hydrogels for 
restoration of biomechanical integrity and for controlled cardiac release of drugs. 
 
Post-myocardial infarct (MI) remodelling has been shown to cause a progressive decline 
in left ventricular performance due to a series of histopathological and structural 
changes that lead to heart failure in one third of the patients. The delivery of hydrogels is 
a promising approach, as first results indicate a reduction in post-MI remodeling by 
limiting increased wall stresses. However, there is no consensus in the present literature 
on the influence of timing of delivery of treatment. The aim of this study was to directly 
compare the effect of injecting an enzymatically degradable polyethylene glycol (PEG) 
hydrogel into the myocardium immediately or seven days after permanent ligation of the 
left anterior descending artery in rats on pathological remodeling. Rats that received 
their treatment delayed by one week had significantly higher fractional shortening values 
(p<0.05) and significantly thicker scars (p<0.05) than those after immediate treatment or 
those of the saline control group. Thus, the timing of post-MI biomaterial application did 
determine the extent to which pathological remodeling could be ameliorated, with 
hydrogel injections into one-week-old myocardial infarcts being superior to immediate 
treatment. The inflammatory responses to the hydrogels and their physical distribution 
in the heart were investigated further within the cardiac tissue. It seems likely that the 
timing of biomaterial injection influences the distribution pattern of the PEG, resulting in 
favorable outcome after delayed hydrogel delivery. 
 
The enzymatically degradable PEG hydrogels were also investigated as a means of 
delivering dexamethasone in a localized and controlled manner. Dexamethasone has 
been the subject of some controversy as post-MI treatment. Although slow release of 
the agent could be demonstrated in vitro, in vivo experiments showed no 
dexamethasone-induced improvement of post-MI cardiac performance, instead they 

















Gene therapy is an area of enormous promise for many pathologies, MI included. 
Adenovirus is a widely used vector but its efficacy is limited by an inflammatory 
response towards infected cells. In this study, the ability of PEG hydrogels with tethered 
dexamethasone to prolong cardiac gene expression when delivered in conjunction with 















1 Investigation of degradable PEG hydrogels  
   as treatment after myocardial infarction 
1.1 Introduction 
1.1.1 Myocardial infarction 
1.1.1.1 Incidence and economic burden of cardiovascular diseases 
In the United States about 81 million adults (and thus more than one in three) suffer 
from one or more types of cardiovascular diseases (CVDs), of which high blood 
pressure, coronary heart diseases and stroke have the highest incidence [1]. In 2007 
cardiovascular diseases resulted in more than 79 million physician office visits as well as 
more than four million visits to emergency departments [2, 3]. Coronary heart diseases 
account for more than half of all cardiovascular events of people younger than 75 years 
of age [4]. During the course of this year, an estimated 785000 Americans will suffer a 
new and about 470000 a recurrent heart attack [5], thus on average every 34 seconds 
an American will experience a myocardial infarction [6].  
 According to the World Health Organization (WHO), in 2004 about 17.1 million 
people passed away due to a cardiovascular disease, which corresponds to 29% of all 
mortalities and thus makes it the number one cause of death worldwide [7, 8]. 
Approximately every minute, someone will die of a coronary event [5]. 
 Obviously the value of human life is beyond analysis, however, estimated direct 
and indirect healthcare costs for 2010 amounted to $503.2 billion [1]. Interestingly, a 
shift from developed to developing countries is being noted [9]: more then 80% of all 
deaths due to cardiovascular diseases occur in low- and middle-income countries, as 
people there have less access to prevention efforts and effective health care services, 




















1.1.1.2 Risk factors 
Established risk factors have to meet three conditions: 1) a high prevalence in several 
populations; 2) a significant independent impact on the risk of the respective disease 
and 3) their control and treatment must result in risk reduction [10].  
About 80 to 90% of people dying from ischemic cardiomyopathy had one or more of 
the following major risk factors that were influenced by their lifestyle and thus the 
disease could have been prevented [11]: hypertension, diabetes mellitus (DM), high 
levels of LDL, smoking, physical inactivity and obesity. 
Hypertension is defined as systolic blood pressure higher than 140mmHg and diastolic 
blood pressure above 90mmHg. Every ten-point increase in diastolic blood pressure or 
twenty-point increase in systolic blood pressure doubles the risk of cardiovascular 
diseases [10].  
Cardiovascular disease death rates among adults with DM are two to four times higher 
than the rates of those, who do not suffer from the disease [1]. The worldwide 
prevalence of DM for all age groups is increasing, with the total number rising from 171 
million (2000) to projected 366 million (2030) [12].  
Cholesterol is transported around the body with low-density lipoprotein (LDL) or high-
density lipoprotein (HDL); high levels of LDL promoting cardiovascular diseases, while 
HDL lowers the risk thereof. As high cholesterol is estimated to cause around a third of 
cardiovascular diseases worldwide, LDL levels of less than 100mg/dL are considered 
ideal [13]. Yet, elevated cholesterol levels are quite common, such as in Canada, where 
about 40% of the people are affected [14].  
Smoking injures the endothelial lining of blood vessels, promotes coronary artery spasm 
as well as the formation of cholesterol plaques and blood clots and elevates blood 
pressure while simultaneously increasing LDL cholesterol levels [10]. Presently cigarette 
smoking is a potent independent predictor of cardiac arrest in patients with coronary 
heart disease [15]. Hence, according to a cohort study conducted in the United 
Kingdom, the mortality was 60% higher in smokers (and 80% higher in heavy smokers) 
relative to nonsmokers [14].  
Physical inactivity doubles the relative risk of coronary heart disease, an increase in risk 
comparable to that observed for high blood cholesterol, hypertension or cigarette 
smoking [16]. Regular exercise results in a significant decrease of diastolic blood 
















Overweight children and adolescents typically have a higher prevalence of established 
risk factors for cardiovascular diseases such as hypertension, hyperlipidemia and 
diabetes later in their lives [18]. 
In industrialized countries, lower socioeconomic groups have a higher incidence of 
cardiovascular diseases along with an increased mortality, as the prevalence of risk 
factors is higher, while the use of medication and access to treatment is lower [10]. In 
developing countries, coronary heart diseases have traditionally been more frequent in 
people with a higher education and more income, but this is beginning to change: as 
the cardiovascular disease epidemic matures, also there the burden shifts towards 
groups of lower socio-economic status [14]. 
Apart from the above-mentioned behavioral risk factors, several studies provide 
consistent evidence of a significant connection between a positive family history and the 
incidence of cardiovascular diseases [19, 20], heart failure [21], sudden cardiac death 
[22] as well as underlying causes such as atherosclerosis [23, 24]. 
 
1.1.1.3 Atherosclerosis leading to myocardial inf rction  
The underlying cause of the majority of coronary heart disease and stroke is 
atherosclerosis, a progressive subendothelial accumulation of lipids and fibrous 
elements, typically protected by a fibrous cap [25].  
 Numerous pathophysiological observations led to the formulation of the response-
to-injury hypothesis of atherosclerosis, which proposes endothelial dysfunction as the 
first step in the development of the syndrome [26]. Some of the causes leading to 
endothelial dysfunction include hyperlipidemia, high blood pressure, diabetes mellitus 
and free radicals caused by cigarette smoking [27, 28]. In fact, it has been shown that 
those risk factors increase the likelihood of atherosclerosis by as much as seven times 
[29]. The injury augments the permeability as well as the adhesiveness of the 
endothelium, leading to the aggregation of lipid-rich macrophages and T-lymphocytes 
within the innermost layer of the arterial wall, the intima [30]. This aggregation is called a 
“fatty streak” and is considered the earliest recognizable lesion of atherosclerosis [30]. 
Eventually, this chronic inflammatory response stimulates the migration and proliferation 
of smooth muscle cells and precedes the development of an “intermediate lesion” [31-
36]. The consequential thickening of the arterial wall can be compensated by gradual 
















Sustained inflammation, however, results in rising numbers of lymphocytes, which 
release hydrolytic enzymes, cytokines, chemokines as well as growth factors [38, 39] 
and provoke further damage as well as focal necrosis [40]. Accumulation of 
mononuclear cells, migration and proliferation of smooth muscle cells as well as the 
development of fibrous tissue lead to the further extension of the lesion, which gets 
protected by a dense fibrous cap that covers a core of lipid and necrotic debris and this 
stage is termed “advanced” [41].  
At some point, it is impossible to compensate the narrowing of the lumen by dilation, so 
that the lesion starts altering the blood flow in the artery [41]. That may result in an 
imbalance between oxygen demand and supply, especially if there is an increased need 
for oxygen, such as during exertion. The resulting predictable chest discomfort 
therefore typically occurs during exercise and resolves at rest or sublingual 
administration of nitroglycerin [42].  
The most dangerous complication of advanced lesions, however, is a sudden rupture of 
the fibrous cap, exposing thrombogenetic material to the blood stream, resulting in 
platelet aggregation, thrombus formation and consequently, a rapid occlusion of the 
artery [43]. As this leads to reduced myocardial oxygen supply, rather than being a 
consequence of increased oxygen demand, such as during exercise-induced angina, 
the subsequent chest pain can even occur at rest, which is one cardinal sign of a 
possible MI [44]. In addition, the patient may experience unspecific symptoms such as 
diaphoresis, light-headedness, nausea and breathlessness and may present with cool 
and pale skin, low-grade fever, irregular pulse, decreased or elevated blood pressure as 
well as neck vein distension [45, 46]. Yet, studies have shown that an estimated 20% to 
40% of first and recurrent myocardial infarcts, especially in elderly patients, women and 
those suffering from diabetes mellitus, are silent and are therefore difficult to diagnose, 
which carries an increased likelihood for delays in seeking medical attention [47-49]. In 
fact, 50% of men and 64% of women, who die suddenly of acute coronary syndrome, 
had no symptoms prior to the event [1]. 
 
1.1.1.4 Diagnosis of myocardial infarction 
The term acute coronary syndrome (ACS) covers a spectrum of acute myocardial 
ischemic states, encompassing the following three types: unstable angina (UA), acute 
non-ST segment elevation myocardial infarction (NSTEMI) and acute ST segment 















In a STEMI the coronary artery is completely blocked and as a result virtually all cardiac 
tissue previously supplied by the affected artery starts to die; ST segment elevation 
seen on the ECG therefore reflects active and ongoing transmural myocardial injury. In 
the less severe NSTEMI the clot only partially occludes the artery and as a result only a 
fraction of the heart muscle supplied by it dies, consequently no ST segment elevation 
is seen in the ECG.  
To further distinguish whether the patient suffers from a NSTEMI or an UA, the 
measurement of cardiac enzymes, which get released into the circulation should there 
be any heart muscle damage, are a sensitive and helpful tool [46]. If the enzymes are 
elevated, an evidence for myocardial necrosis, the patient suffers from a NSTEMI, if 
they are within normal range the patient has an UA. 
Patients presenting with chest pain are initially treated as if an MI has occurred and are 
then carefully investigated to establish a more precise diagnosis, as this determines 
their further treatment [51, 52]. Thus, in order to classify the patient into one of the 
above groups, it is essential to obtain an ECG, to quantify serum cardiac biomarkers 
and to look for imaging evidence of new loss of viable myocardium or new regional wall 
motion abnormalities [53].  
According to the WHO guidelines, which were refined in 2000, diagnostic of an MI is a 
combination of two out of three characteristics: typical symptoms, cardiac Troponin 
elevation or ECG changes indicative of ischemia, such as pathological Q-waves or ST-
elevation/depression [54].  
 
1.1.1.5 Post-MI remodeling  
The mechanism, with which the myocardium responds to the ischemic injury, is a 
complex multifactorial process known as left ventricular (LV) remodeling [55].  
 Briefly, the occlusion of a coronary artery leads to irreversible death of 
cardiomyocytes in the area previously supplied by it, and, depending on the infarct size, 
an initial thinning and distension of the infarcted myocardium [56]. This is followed by 
the initiation of a neurohormonal cascade that aims to compensate for the lack of 
contractile function and subsequent hypertrophy of the non-infarcted myocardium, 


















Cardiac output can be maintained initially and may even result in hyperfunction of the 
left ventricle, but over time, these compensatory mechanisms fail, resulting in a 
progressive deterioration of cardiac performance [55, 56]. The end result is a dilated, 
underperforming ventricle, causing the clinical symptoms of heart failure (HF) [57]. 
  
The structural and mechanical changes of a healing myocardial infarct have been 
divided into four phases: 1) acute ischemia; 2) necrotic phase; 3) fibrotic phase and 4) 
the remodeling phase [58]: 
 
1) Acute ischemia phase 
The first phase refers to the initial six hours after permanent coronary artery occlusion, 
during which the infarcted myocardium undergoes a transition from an active, force-
generating material to a passive, viscoelastic one [58].  
Generally, hypoxia causes a change from oxidative to glycolytic energy production with 
increased glucose consumption, lactic acid production and consequently a decreasing 
intracellular pH [59, 60]. The latter is an important regulator of cardiac performance and 
has its steady state at around 7.1-7.3 [61]. It declines moderately with an increase in 
heart rate [62, 63] but more severely if the myocardium is in an ischemic state [64]. The 
resulting acidosis is partly responsible for arrhythmia and failure of contraction [65-67]. 
 Simultaneously matrix-associated glycoproteins start to break down as early as 40 
minutes after infarction, while collagen and elastin fibers get damaged in the first two 
hours, possibly due to early activation of matrix metalloproteinases (MMP) [68-70]. 
Within 30 seconds after experimental infarct induction, no effective work is performed 
by the ischemic myocardium; instead, work is being done on rather than by the 
segment [71]. Thus the left ventricle appears to be more compliant than usual shortly 
after coronary artery ligation [72], but becomes less compliant than normal a few hours 
afterwards [73]. Apart from the disruption of structural proteins such as collagen or titin, 
the initially increased LV compliance could be explained with a loss of coronary 
perfusion pressure in the occluded vessel, while the subsequent stiffening of the 
infarcted myocardium is likely due to edema [74-76].   
With non-contractile, dying tissue forms the ischemic area, infarct expansion induces an 
increase of the volume load, which, in turn, leads to an augmentation of the pressure 
















The consequential decline of ejection fraction (EF) has been shown to be in direct 
proportion to the size of the infarct [79]. However, due to the Frank-Starling 
mechanism, the increasing LV volume augments the contractility of the remaining 
healthy myocardium and therefore the stroke volume, so that cardiac output initially 
remains relatively normal [80]. Thus, initial post-MI remodeling could be beneficial and 
could even promote survival, however, it holds deleterious long-term hemodynamic 
consequences [77]. 
 
2) Necrotic phase 
This period is characterized by inflammation and necrosis, starting with infarct stiffening 
six hours post-MI and ending after about one week [58].  
Removal of dead muscle occurs [81], while collagenase and gelatinase activity of MMP-
1, MMP-2 and MMP-9 is elevated, continuing with the disruption of the collagen 
network of the myocardium [68, 70, 82-89]. Newly formed collagen is not yet properly 
crosslinked [90, 91], which could be an explanation for the side-to-side slippage of 
cardiomyocytes that hypothetically contributes to their elongation with subsequent 
thinning of the left-ventricular wall [77, 92]. Thus, it is not surprising that infarct rupture 
is most likely to occur during this period [93-96]. Although overall rare in its occurrence 
(incidence ranging from 0.8%-6.2%), ventricular free wall rupture (VFWR) remains a 
dreaded complication of MI as it accounts for as much as 15% of the in-hospital 
mortality and is the second most common cause of death after cardiogenic shock 
secondary to an acute myocardial infarction [97, 98]. Interestingly, according to the 
National Registry of Myocardial Infarction (NRMI), cardiac rupture is seen more often in 
patients undergoing thrombolysis (12.1%) than in patients who don’t (6.1%, p<0.001), 
typically within the first 24 to 48 hours after the infarct has occurred [99, 100]. Similarly, 
in the Thrombolysis in Myocardial Infarction II trial (TIMI-II), cardiac rupture was the 
cause of death in 16% of patients dying within 18 hours of thrombolytic therapy [101]. 
The explanation seems to be an increased incidence of intramyocardial hemorrhage 
caused by the thrombolytic therapy, which generates plasmin, a non-specific 
proteolytic enzyme that boosts collagen breakdown [102-104]. 
The activation of the immune system during the necrotic phase follows the same 
pattern as after any infection: most microorganisms encountered by a healthy individual 
are identified and eliminated within hours by defense mechanisms that are not antigen-















The heart itself possesses all components of the innate immune system, including 
pattern recognition receptors and effector proteins [105, 106]. Although it is commonly 
accepted that the innate immune system is activated by microbial patterns, Matzinger 
and co-workers assumed that cell damage rather than foreignness is what triggers an 
immune response [107]. In support of this hypothesis, they have proven that, in the 
absence of any foreign pathogens, resting dendritic cells can be activated by necrotic 
cells [107], such as cardiomyocytes that have been damaged by ischemia [105, 108-
110]. That results in the release of intracellular proteins and triggers the launching of 
pattern recognition receptors such as Toll-like receptors (TLRs), the transcription 
nuclear factor kappa B (NF-κB) and complement [105, 108, 109]. NF-κB, in turn, 
activates genes involved in inflammation, cardiomyocyte growth, contractile function 
and death as well as extracellular matrix remodeling [111]. Adhesive proteins such as 
fibronectin [112, 113], laminin and collagen type IV [114] emerge at about three to four 
days post-MI in animal models. 
 
3) Fibrotic phase 
The fibrotic phase is the period of healing, which is dominated by new collagen 
deposition, starting one week post-MI with rapidly increasing collagen content and 
ending as soon as the collagen accumulation slows down, roughly after three weeks 
[58]. During this phase infarct stiffness peaks, with segment lengths changing not more 
than 2% over the cardiac cycle, which results in impaired filling and thus in diastolic 
dysfunction [115].  
 
4) Remodeling phase 
Only the onset of this final period can be defined, since a healing scar is dynamic, living 
tissue that, because of its ongoing activity, may never reach a steady, mature 
configuration [116]. Due to increased crosslinking of collagen, the dominant effect 
during the remodeling phase is the shrinkage of the scar [117-119]. Scar shrinkage 
appears to reverse infarct expansion: by reducing scar size and consequential cavity 
dilation, wall motion abnormalities can partially improve [119-121]. However, patients 
suffering from a large infarct may still experience functional impairment, as scar 



















Fig. 1: Ventr icular di latat ion associated with progressive heart fa i lure. Figure adapted from 
Jessup and Bronzena [124] 
 
In contrast to early infarct expansion, late ventricular enlargement after myocardial 
infarction, is caused by an increase in the segment length of the remaining non-
infarcted tissue [125]. That places the non-infarcted myocardium at a mechanical 
disadvantage, with higher systolic stresses required to eject against a given pressure 
[58]. The rising systolic and diastolic volumes, which lead to global ventricular dilation 
and increased wall stresses, result in the cardiomyocytes losing the capacity to shorten 
effectively, leading to further stretching and continuing decrease in cardiac performance 
[126].  
The physics behind this mechanism can be explained by the Law of Laplace (Equation  
1), where the stress in the wall of a round chamber (T) is directly related to the pressure 







Eq. 1: Law of Laplace. As pressure and radius increase, the LV free wall thins, which augments cardiac 
wall stress and ultimately leads to even more dilation, thinning and stress [126].  
 
The resulting HF describes a state in which cardiac output is insufficient in meeting the 
body’s requirements for oxygen and nutrients. The failing heart is characterized by 
reduced rates of shortening and relengthening (decreased force production) and 















One of the first symptoms resulting from an inadequate performance of the heart might 
be shortness of breath, which has been used as basis to classify the severity of HF by 
the New York Heart Association in 1964 (NYHA 1: no breathlessness, NYHA 2: 
breathlessness on severe exertion, NYHA 3: breathlessness on mild exertion and NYHA 
4: breathlessness at rest) [132]. Apart from that, poor cardiac output can cause edema, 
skeletal muscle fatigue and generalized tiredness, resulting in HF being disabling and 
possibly severely reducing a patient’s quality of life [124, 133, 134]. The staging criteria 
for HF has been updated by the American College of Cardiology/American Heart 
Association in 2001: Stage A: patient at high risk for developing HF, but who does not 
yet demonstrate impaired LV function, Stage B: asymptomatic patient with structural 
heart disorder, Stage C: patient with current or past symptoms of HF, which are 
manageable with medical treatment, Stage D: patient that suffers from severe HF and 
requires advanced treatment strategies such as continuous inotropic infusions or heart 
transplant [135].  
 
1.1.1.6 Management and prognosis of myocardi l infarction 
Management  
An acute MI is a medical emergency that requires prompt recognition, since the 
beneficial effects of reperfusion therapy are substantially higher within the first two hours 
after the onset of symptoms [136-138]. A sudden cardiac arrest victim’s chances of 
survival fall rapidly for every minute that defibrillation was delayed to 5% at 15 minutes 
[139-142]. Overall survival rates improve by up to 50% if treatment begins within one 
hour, however, most patients are admitted to the hospital 2.5 to three hours after onset 
of symptoms [143]. 
Every patient presenting with chest pain should be managed as if the pain was 
ischemic in origin until clear evidence of the contrary is established [46]. Thus, the 
simultaneous accomplishment of the following goals is fundamental: relief of ischemic 
chest pain, assessment and optimization of the hemodynamic status and confirmation 
of the diagnosis, as well as timely initiation of antithrombotic and reperfusion therapy 
[53]. Patients are supposed to be started on aspirin [144, 145], nitroglycerin, morphine 
sulphate, betablockers, calcium channel blockers and heparin [46, 53], while the right 
















Patients presenting with ST-segment elevation benefit from reperfusion through 
thrombolysis [138, 147] or percutaneous coronary intervention (PCI) [148], which results 
in a statistically significant decrease in death rates, cardiogenic shock, heart failure and 
pulmonary edema [149]. Fibrinolytic therapy, however, does not improve the clinical 
outcome of patients presenting with NSTEMI and is therefore contraindicated [46, 150]. 
Twenty-eight studies conducted between 1977 and 2007 found that revascularization 
by PCI in conjunction with medical therapy or coronary bypass surgery in patients with 
non-acute coronary artery disease significantly improves survival compared to medical 
treatment alone [151]. It can be concluded that primary PCI is the superior alternative to 
fibrinolysis within 90 minutes after symptom onset, while the latter is appropriate for up 
to 12 hours if PCI was unavailable in the first two hours [148, 152, 153].  
Post-MI, patients are treated with several long-term medications to improve function 
and to prevent secondary cardiovascular events. The main goal is to reduce the load in 
order to lessen distending or deforming forces [77]. ACE-inhibitor therapy can be seen 
as a means to moderate the increase in apical wall stress and to normalize the dilation 
of the left ventricle [154-156]. It acts, in part, by reducing the preload and therefore the 
LV operating volume [157]. If LV dilation is avoided, then the pure hypertrophic 
response of surviving myocytes gives hemodynamic benefit [158]. Betablockers act by 
reducing the afterload and thus the intracavity systolic pressure [77]. Further benefits 
are obtained when antiplatelet drug therapy [159], statins [160, 161] as well as 
aldosterone antagonists [162] are added to the long-term medication. 
 
Prognosis and the search for therapeutic alternatives  
Long-term progressive remodeling of the LV can still occur up to two years after 
myocardial infarction [163] and is the leading cause of systolic dysfunction and HF - in 
fact, according to 13 multicenter HF treatment trials involving more than 20000 
patients, coronary artery disease was the underlying cause in almost 70% of the cases 
[164]. Unfortunately, there are only a limited number of options available to prevent 
progression to HF, such as medicamentous treatment, which is supposed to improve 
systolic function and decrease the workload [165, 166], biventricular pacing [167, 168] 
or mechanical approaches including CorCap (Acorn Cardiovacular Inc.) and HeartNet 
(Paracor Medical Inc.), employing Dacron and nitinol wraps to provide physical support 
















Alternatively, surgical approaches such as the endoventricular patch plasty (Dor 
procedure) and partial left ventriculectomy (Batista procedure) aim to improve 
performance by giving a spherical dilated ventricle a more elongated shape [171, 172].  
 Although all those therapy options are able to delay remodeling or HF, none is able 
to reverse it. Consequently, more than 50% of patients that were given the diagnosis of 
HF are dead within five years [173]. Organ transplantation remains the treatment option 
with the most favorable outcome, offering a five-year survival rate of around 65%, but is 
limited by a general shortage of donor hearts [174]. As a result, most of those patients 
are left with ventricular assist devices used as bridge to transplant or for destination 
therapy [127, 175, 176] or ultimately hospice care.  
 
The poor long-term prognosis of heart failure patients and immense public health 
implications have fuelled interest in trying to establish therapeutic alternatives to those 
detailed above.  
Research has shown that there is extensive proliferation of human cardiomyocytes 
during human fetal life, but that it slows down dramatically around the time of birth 
[177]. In a groundbreaking approach to substantiate this hypothesis, Bergman et al. 
took advantage of the integration of 14C into DNA, generated by nuclear bomb testing 
during the Cold War [178]. Based on the post-mortem 14C content in human 
cardiomyocyte DNA, they were able to conclude that at the age of 25, indeed only 1% 
of cardiomyocytes are replaced annually while the rate declines to 0.45% in aging 
hearts and that less than half of cardiomyocytes are exchanged during a normal life 
span [178]. Thus, in contrast to zebra fish, which are able to fully regenerate hearts 
within eight weeks even after 20% ventricular resection, cardiac regeneration in 
mammals is hindered by the fact that renewal of heart muscle is virtually absent [179, 
180]. In view of that, Anversa et al. managed to identify a lineage of cardiac stem cells 
(CSCs) residing in the heart [181], but in the circumstance of acute muscle cell death 
from MI, their regenerative capacity is grossly inadequate to compensate for the loss of 
up to one billion cardiomyocytes [182-184]. Consequently, tremendous scientific as well 
as public interest and excitement have been generated by the possibility of stem cell 
based myocardial repopulation and the idea of rebuilding the injured heart from its 
component parts [182, 184, 185]. Ideally, transplanted cells would imitate the lost 
myocytes morphologically and functionally and establish electrical connectivity with the 















A wide variety of cells have been considered for cardiac therapy [183]:  
Skeletal myoblasts are resistant to ischemia and can improve ventricular function [186-
189]. However, they do not couple with resident cardiomyocytes electromechanically 
and therefore do not beat in synchrony with the remaining myocardium [190-193]. 
Tests conducted on bone-marrow-derived hematopoetic stem cells (HSCs) have 
generated hope by suggesting potential transdifferentiation into cardiomyocytes [194-
196], while other studies were unable to confirm this hypothesis [197, 198]. The small 
amount of detected cardiomyocytes is more likely generated through cell fusion [199]. 
Bone marrow also contains mesenchymal stem cells (MSCs). The latter might be able 
to differentiate into cardiomyocytes, but at an extremely low rate [200, 201]. Their 
beneficial effect can most likely be explained with paracrine growth factor support for 
other cells present in injured myocardium [202]. Taken together, no consensus exists 
on whether or not bone-marrow-derived cells are able to improve cardiac function [203-
207]. Adult cardiac stem cells represent another potential cell type for cellular 
cardiomyoplasty [208-211]. However, sourcing, isolating and expanding those cells 
might be challenging, possibly involving invasive procedures. Moreover, harvesting 
sufficient numbers seems ironic, given that the heart is known for its lack of 
regenerative capacity [191]. Promising results have been achieved with embryonic stem 
cells (ESCs), as they have the unquestioned ability to differentiate into cardiomyocytes 
and possess the cellular elements necessary for electromechanical coupling with the 
native myocardium [212-215]. However, hurdles that stand in the way of the clinical use 
of these cells are immunological rejection, the predisposition to form teratomas [216] as 
well as ethical considerations. An alternative might be induced pluripotent stem cells 
(iPS), which are comparable to natural pluripotent stem cells such as ESCs, but are 
artificially derived from non-pluripotent cells, usually adult somatic cells. That way, 
researchers have access to pluripotent stem cells, while avoiding the controversial use 
of embryos [217]. Nelson et al. were the first ones to successfully demonstrate iPS-
based cardiac repair after myocardial infarction [218]. However, similar to ESCs, iPSs 
hold an increased risk of tumor formation [218].  
 A critical factor that determines the success of stem-cell therapy is the retention of 
the cells. Most intramyocardially injected cells are lost through leakage into the 
vasculature or squeezed back out of the injection site [219, 220]. The contracting 
myocardium, being a mechanically taxing environment, contributes to further cell loss 















Teng et al. revealed a cell retention rate of only 11% in the beating porcine heart versus 
67% in the non-beating heart [221]. Another study showed that about 1% of infused 
bone marrow cells are retained in the heart and that less than 3% of MSCs 
administered by direct injection persist after two weeks [222]. It seems that most of the 
cells relocate to the lungs, spleen, liver, kidneys and non-infarcted cardiac tissue [223, 
224]. Taken together, it can be estimated that about 90% of transplanted cells have 
disappeared within one week [191]. To transplant adequate numbers of cells into the 
myocardial region of interest and to achieve maximum cell retention within that area, a 
sufficiently large cell graft with suitable structural and functional properties is needed 
[183, 225]. Survival and integration of transplanted cells can be improved by implanting 
them as monolayer sheets [226] or by embedding them in matrices such as collagen 
[227, 228], Matrigel [229-231], chitosan [232], fibrin [233-235] or α-cyclodextrin/MPEG-
PCL-MPEG self-assembling hydrogel [236]. 
  
Despite encouraging results, it is still not fully understood which cell type has the 
greatest potential to repair myocardium and also it is not verified whether or not injected 
cells contribute to functional improvement at all. Interestingly, beneficial effects might be 
a result of any intramyocardial material injection. Wall and colleagues used a finite 
element model of an ovine infarcted LV to assess the theoretical effect of injecting any 
non-contractile biomaterial into ischemic myocardium [237]. Functional assessments in 
most studies are based on ejection fraction (EF), a common clinical metric of heart 
performance. Since the EF is calculated from geometric factors, increased EF values 
might not be a reflection of true functional improvement but could just as well be due to 
an increased wall thickness and therefore changes in ventricular geometry. The sheer 
presence of a material leads, on top of that, to a local reduction of elevated myofiber 
stresses [237]. These finite element models provide the hypothetical basis for an 
increasing interest in injecting decellularized biomaterials to try and prevent progression 
to heart failure [126].  
 
1.1.2 Biomaterials for the treatment of myocardial infarcts 
A biomaterial, by definition, is a non-viable substance that is used in a medical device 
















In order to enable tissue regeneration, it should allow the substitution of itself by safely 
degrading at a rate similar to that of the new tissue creation, eventually being 
completely removed from the body without having produced toxic by-products [238]. 
 Intramyocardial biomaterial injection following MI has shown potential as a method 
to improve cardiac performance in the face of progressive HF and has the advantage of 
being less invasive than implanting in vitro-engineered tissue or an epicardial patch 
[126, 240]. Hence, an exciting field of biomaterial research that has opened up and 
grown rapidly is the use of injectable polymers (i.e. hydrogels). Indeed, initial test results 
have indicated increased wall/scar thickness [241-244], reduction of adverse LV 
remodeling [241, 244, 245], attenuated infarct expansion [246, 247] and improvement 
of functional parameters [241, 242, 247]. 
Hydrogels are defined as three-dimensional polymer networks that absorb up to 
thousands of times their dry weight in water [248, 249], which results in properties that 
are similar to many tissues and as such hydrogels became an attractive extracellular 
matrix analogue [250-252]. Consequently, they are being used as wound dressings and 
biomedical implants [253], for tissue engineering [251, 254, 255] and as barrier material 
to regulate adhesion [256]. Moreover, hydrogels facilitate the incorporation of various 
chemical functionalities to generate complex architectures; they offer good transport of 
nutrients to and products from cells (high diffusivity within the polymer network) as well 
as an aqueous environment that can protect cells and delicate pharmaceuticals [248, 
257]. The latter makes hydrogels, apart from the above-mentioned applications, also 
suitable for drug delivery systems [257, 258]. In fact, the incorporation of 
pharmaceuticals into hydrogels provides a means for continuous local delivery of low 
doses. That increases the persistence of a drug at the disease site while confining its 
availability to a target region, which helps avoiding unwanted systemic side effects 
adverse to healing [257, 258].   
A potential drawback of hydrogels is their low mechanical strength, which might be 
insufficient for a mechanically taxing environment such as the beating heart. In fact, 
hydrogels that could be passed through a needle might be too weak to provide 
structural support. To overcome this challenge, various design strategies have been 
employed, which allow the formation of the hydrogel structure following injection into 
the myocardium, such as in situ crosslinking [244, 259], photo-induced polymerization 
















The in situ transformation from liquid precursors to solid final forms has the additional 
advantage of enabling the minimally invasive delivery of larger implants. 
 
There are several ways of classifying hydrogels. One is based on the mechanism by 
which the crosslinks within the networks are formed: physical gels (“reversible”) shape 
by molecular self-assembly due to secondary forces, while chemical gels (“permanent”) 
are formed by covalent bonds. Intermediate-type gels polymerize as physical gels but 
are additionally crosslinked by specific chemical interactions [248, 249]. A perhaps 
more practical approach to categorizing hydrogels is according to their natural or 
synthetic origin; selected examples listed in Table 1 and elaborated on below: 
 
 Table 1 : Examples of  hydrogels from natural  and synthetic mater ials 
Natural materials Synthetic materials 
Fibrin 
Collagen and gelatin 
Alginate 
Hyaluronic acid (HA) 
Self-assembling peptides (SAP) 
N-isopropyl acrylamide (NIPAAm) 




1.1.2.1 Natural polymer matrices 
Fibrin 
Fibrin is the major component of blood clots and thus plays an important role in natural 
wound healing by forming a three-dimensional crosslinked network [126]. It forms a gel 
by enzymatic cleavage of fibrinogen in the presence of thrombin [251]. During the 
process of new tissue formation, fibrin gradually becomes degraded by plasmin or 
matrix MMPs produced in the pericellular milieu of cells invading and replacing the 
temporary matrix [249]. In terms of clinical applications, fibrin is widely used as tissue 
sealant in surgery, named “fibrin glue”; a mixture of concentrated fibrinogen and 
thrombin [265-267]. Because of its slow lysis, fibrin glue has also been explored as 
provisional reservoir to deliver protein therapeutics [268], cells [269] or DNA of genes 

















Fibrin eventually became the first injectable scaffold to be used to increase cell retention 
when transplanted into ischemic myocardium and even proved to decrease infarct size 
when injected alone [235]. Subsequently, fibrin displayed a multitude of beneficial 
effects [234, 272, 273]. Hence, the injection into one-week-old infarcts prevented wall 
thinning and maintained fractional shortening over five weeks after injection although the 
material was resorbed within two weeks [234]. Additionally, it has been shown that 
fibrin injection is able to reduce infarct size and increase arteriole density, as compared 
to the control group [272, 274]. In a study performed on infarcted porcine hearts, 
researchers could confirm increased wall thickness as well as prevention of infarct 
expansion; however, they were unable to show functional improvement [246].  
Overall, fibrin injection is not consistently associated with functional improvement [126], 
which, in part, could be explained by its limited mechanical strength and duration [251].  
 
Collagen and gelatin  
Collagen is the most abundant protein in mammalian tissues [275] and is the main 
component of the ECM [251]. It meets many of the desired parameters, as it is built 
from amino acid sequences that are recognized by cells and degraded by enzymes 
secreted from those cells. Thus, collagen-based gels have been employed for the 
reconstruction of liver [276], skin [277] and blood vessels [278]. Collagen injection after 
myocardial infarction has lead to increased ejection fraction relative to the control group 
at six weeks post-MI. [242]. However, neither angiogenesis nor cell infiltration could be 
detected in that study. Their lack, however, has not been universally observed, as a 
different research group was able to demonstrate fibroblast infiltration as well as 
angiogenesis [274]. When considering it as treatment option, one also has to keep in 
mind though that collagen gels are mechanically weak and, since derived from animal 
skin, bone or tendon, potentially immunogenic [249, 279, 280].  
 Gelatin is a degraded derivative of collagen. Critical properties such as cell 
adhesiveness and proteolytic degradability are retained in gelatin [249]. Similarly to 
collagen, gelatin has limited mechanical strength and degrades even quicker than its 
parent molecule [251]. Its injection into infarcted rat hearts has shown no functional 
improvement four weeks post-MI [281].  
 The injection of Matrigel, a porous liquid collagen compound, led to homogeneous 
engraftment within the ischemic myocardium and adapted to the host organ collagen 















Matrigel injection into ischemic hearts resulted in improved fractional shortening and 
wall thickness four weeks after treatment [230]. However, according to Wall et al. the 
effects seen by Kofidis and colleagues could be explained by large amounts of material 
being injected (corresponding to 50% of the normal ventricular wall volume), resulting in 
geometrical changes instead of the claimed functional regeneration [237]. Moreover, as 
Matrigel is derived from a mouse sarcoma line, its clinical application remains 
questionable due to the potential risk of tumor induction [126, 282].  
One study compared fibrin with collagen and Matrigel, all of which were injected into 
one-week-old infarcts of separate groups of rats. The report showed that all three 
materials generated a similar increase in myofibroblast infiltration and capillary density 
relative to saline injection, however, the study was lacking data on cardiac function 
[274]. Fibrin, collagen and Matrigel have the disadvantage of gelling prematurely during 
catheter delivery due to their rapid gelation kinetics [282]. For fibrin, however, that could 
be overcome by using double-barreled catheters.  
 
Alginate 
Alginate is an anionic linear polysaccharide composed of beta-D-mannuronic acid and 
alpha-L-glucuronic acid that is found in brown seaweed. When complexed with 
multivalent cations such as Ca2+, alginate forms a hydrogel [283]. The material 
properties of alginate have been reviewed and studied extensively [284]. As it is cost-
effective, bioinert as well as non-toxic, interest has been generated for its use in the 
food, pharmaceutical and medical device industry. Thus, alginate-based biomaterials 
have been applied successfully for the controlled delivery of growth factors [285-287] 
and drugs [288] as well as for tissue engineering [289, 290]. Based on its unique ability 
to undergo a phase transition utilizing the calcium present in heart tissue upon injection 
into the LV wall, its therapeutic potential has also been investigated in the context of MI. 
It has been shown to reduce post-MI remodeling and dysfunction as well as infarct 
expansion both in rats [241, 291-293] as well as in swine [245]. Functional 
improvements after alginate injection could be shown for up to five to eight weeks after 
treatment, even if the material was injected several weeks after infarct induction [273].  
 However, alginate may not be an ideal material as it undergoes a somewhat 
uncontrolled degradation via a process involving loss of divalent ions into the 
surrounding medium, which eventually results in a decrease in mechanical stability and 















In addition, stimulation of inflammatory cells have been reported [294, 295]. 
Furthermore, the molecular weights of many alginates are typically above the renal 
clearance threshold [251]. 
 
Hyaluronic acid (HA) 
Hyaluronate plays a significant role in wound healing, cell proliferation and differentiation 
[296] as well as cell adhesion and motility [297, 298]. It has shown promising results 
when used for tissue engineering of artificial skin [299], dressings for wound healing 
[300], soft tissue augmentation [301], ophthalmic surgery [302] as well as for the 
treatment of joints [303] and drug delivery [304-306]. Yet, as for any other biomaterial of 
natural origin, hyaluronate requires meticulous purification to eliminate impurities and 
endotoxins that might transmit diseases or elicit an immune response [307]. 
Furthermore, hyaluronate gels are characterized by low mechanical properties [251].  
 Ifkovits and colleagues investigated the influence of different mechanical strengths 
of HA on ovine infarcts, for which Methacrylated Hyaluronic acid (MeHA) with 30% and 
60% methacrylate substitution was injected post-MI [308], the higher percentage 
creating a greater stiffness. While both concentrations showed similar degradation 
rates, cellular responses as well as tissue distribution patterns, the injection of the stiffer 
material resulted in less infarct expansion and LV dilation compared to the weaker one 
and was associated with higher cardiac output and EF after eight weeks [308]. That 
coincides with the findings of Wall et al., that when it comes to normalizing increased 
wall stresses, stiffer materials show greater benefits [237].  
 
1.1.2.2 Synthetic polymer matrices 
Although synthetic biomaterials are more likely to trigger inflammatory and foreign body 
reactions, one huge benefit is that every stage of their synthesis can be controlled by 
the engineer, thus allowing material properties to meet specific design objectives, such 
as structure (crosslinking density) and tailored properties (degradation, mechanical 
strength as well as chemical and biological response to stimuli) [255, 279]. Synthetic 
hydrogels offer the advantage of being biomimetic of the native biochemical and 
structural matrix composition [282], while eliminating the risk of pathogen transmission  
and immunogenicity [249]. Three groups of synthetic materials, widely used for 















Self-assembling peptides (SAP) 
In nature, there is an abundance of materials that self-assemble to create larger 
structures, including lipids and proteins. Being 8-16 amino acids long, self-assembling 
peptides are composed of alternating hydrophilic and hydrophobic residues [309]. In 
water they form stable β-sheets, which upon exposure to physiological salt 
concentration or pH form a stable hydrogel, consisting of more than 99% water [310, 
311]. Adapting that principle to synthetic materials [312], peptides have been developed 
that are able to self-assemble into macroscopic materials suitable for tissue engineering 
[313] and cardiac wall therapy [314]. Davis et al. could show that the injection of 
nanofibers into the non-infarcted LV free wall significantly augmented endogenous cell 
recruitment [315]. They demonstrated in another study the feasibility of sustained IGF-1 
delivery and, when combined with cell therapy, improved systolic function after 
experimental myocardial infarction [316]. In a further study conducted by this group the 
injection of nanofibers into infarcted hearts showed sustained improvement of fractional 
shortening over three months, while the injection into uninfarcted hearts resulted in 
temporarily impaired systolic function [317]. Nanofiber injection into infarcted rat 
myocardium was unable to increase myocardial cell proliferation and neovascularization 
[318, 319]. This could perhaps be explained by too little material being injected that, in 
addition, is not mechanically robust [126]. 
 
N-isopropyl acrylamide (NIPAAm) 
Thermoresponsive materials, such as NIPAAm, can be dissolved in water below their 
transition temperature of 32°C but turn into a hydrogel when reaching body 
temperature [126]. That gel has the disadvantage of being non-degradable, however, 
that can be overcome by co-polymerization with degradable polymers [320, 321] or 
incorporation of enzymatically cleavable peptide crosslinkers [322]. The mechanism of 
temperature-dependent phase transition may be ideal for cell delivery, as the timing of 
the polymerization is not set, but simply depends on the temperature change upon 
introduction to the body [251]. The injection of acrylic acid and hydroxyl ethyl 
methacrylate-poly(trimethylene carbonate) (HEMAPTMC), a co-polymer of NIPAAm has 
proven to prevent the progression of cardiac dilation as well as post-MI remodeling and 
















Wu et al. explored a gel made of Poly(ε-caprolactone) (PCL)-grafted dextran chains, co-
polymerized with NIPAAm monomer, which becomes degradable through cleavage of 
dextran [323]. Its injection into four-day-old MIs lead to significantly improved EF relative 
to the saline control group and to a considerably thicker LV wall, which was still evident 
at four weeks post-MI [247]. As all material had disappeared after four weeks, it is 
unclear, whether the observed effect was due to cell infiltration or an increased collagen 
deposition. An important factor that needs to be taken into account, is the potential 
toxicity and carcinogenicity of NIPAAm [324]. 
 
Poly(ethylene glycol) hydrogel matrices (PEG) 
PEG polymers form aqueous solutions containing linear or branched macromers with 
reactive groups that can be crosslinked into hydrogels either spontaneously or via 
photopolymerization. One particular chemistry that is of great interest is the Michael-











































Fig. 2a: Chemistry of Michael- type addit ion reaction  between acrylate- as well as vinyl sulfone-
















Fig. 2b: Polymerization of mult iarm PEG hydrogels. Here a 4-arm macromer is illustrated, 
however, the number of arms can vary. Figure modified after Zisch et al. [249]  
 
 
PEG macromers have the advantage of being highly hydrophilic, which means that they 
do not cross cell membranes, while being generally non-adhesive to cells and proteins 
[249]. As bioactivity is important for cellular adhesion, proliferation, growth and therefore 
tissue regeneration, its lack can in some cases even be a disadvantage [282]. However, 
through co-polymerization with other macromolecules, such as the integrin binding 
peptide RGD, one can easily promote the survival of adherent-dependent cells within 
otherwise bio-inert PEG hydrogels [350]. Hence, the versatility of the PEG macromer 
chemistry together with its excellent biocompatibility has, over the past few decades, 
stimulated significant research and extensive use of numerous intelligently designed 
PEG hydrogel systems for several medical applications [325-330], such as the control 
of adhesion formation [344-347], to release adhesion-preventing drugs [348, 349] and 
to control healing of arterial injuries induced by balloon angioplasty [347].  
 
Christman et al. suggested to use an injectable polymer that is non-degradable for 
long-term beneficial effects on post-MI heart remodeling [240]. Hence, to our 
knowledge, we were the first laboratory to use the Michael-type addition reaction to 















The intramyocardial injection of a PEG-based hydrogel following permanent coronary 
artery occlusion was used in order to prevent post-infarct remodeling and progression 
to heart failure. The thiol-bearing crosslinker caused spontaneous in situ polymerization 
and was non-degradable. Thus, the PEG hydrogels remained at the injection site 
indefinitely and showed promising results at 28 days post-MI (reduced end-diastolic 
diameters). However, after three months, despite the inert nature of PEG hydrogels, an 
extensive macrophage response was detected [244], which may be a prove for the 
damaging role that chronic inflammation can play.  
Therefore a degradable PEG hydrogel might be superior to a non-degradable one, 
which is why numerous biomaterials have been designed to degrade by ester hydrolysis 
[255]. Yet, more common in vivo is the enzymatic cleavage of structural proteins of the 
extracellular matrix, such as collagen, by cell-secreted proteases [331-334]. Cell-
induced proteolysis is essential for 3-D cell invasion, otherwise the ECM would have a 
barrier function and thus hinder migration [335]. Consequently, PEG hydrogels with 
biological functionalities specifically associated with cell migration have been developed, 
making them sensitive to degradation by MMP [336-338], plasmin [339] or both of 
these protease families [331, 340, 341]. That way, the degradation process is directly 
linked to the healing progress of the responding tissue. This “cell-dictated” hydrogel 
degradation is extremely useful for tissue regeneration as it eliminates the risks of 
incorrect network degradation or therapeutic liberation profiles and is therefore strongly 
desired in essentially every in vivo tissue engineering approach [342]. 
After degradation, PEG hydrogels are eventually excreted via urine or feces [343].    
 
1.1.2.3 Host response to biomaterials   
Biocompatibility is crucial for the in vivo use of any biomaterial. Although commonly 
used biomaterials are supposed to be physically and chemically stable, inert as well as 
nontoxic, a host inflammatory reaction is a natural response to tissue damage and the 
presence of a foreign object [351, 352]. Yet, extent and duration of the inflammatory 
process directly influence biomaterial integrity [353] and can result in serious iatrogenic 
consequences such as osteolysis next to artificial joints, stress cracking of pacemaker 
leads as well as capsule contracture of mammary prostheses [354]. Inflammatory 
responses to biomaterials involve a number of dynamic, interdependent and multi-
















Firstly, biomaterials spontaneously acquire a film of nonspecific host protein immediately 
upon implantation; a process that does not occur during physiological wound healing 
[354, 356]. The three predominating host plasma proteins are albumin, IgG and 
fibrinogen [357, 358]. Those proteins, found on the biomaterial surface, are recognized 
by leukocytes, which subsequently adhere via several adhesion ligand-receptor 
superfamilies [359]. Since the implant is considerably larger than the adhered 
macrophages, they are unable to phagocytose the foreign body [356]. That triggers a 
chronic inflammation at the biomaterial surface as well as the fusion of macrophages, 
which form multinucleated foreign body giant cells (FBGC); cells that are frequently 
observed for the duration of the implant [360]. The formation of FBGCs is unique to the 
macrophage phenotype, thus their presence can be exploited as a histopathological 
marker for chronic inflammatory or foreign body reaction [361]. The final step of the 
foreign body reaction is reached as soon as the implant is surrounded by a dense, 
avascular, fibrous capsule, typically 50-200µm thick [356].  
Non-fouling coatings (i.e. coatings that are resistant to protein-adsorption), including 
hydrogels, polymeric films and brushes, have been investigated to modulate 
inflammatory responses to implanted biomaterials [355]. Of all hydrogels, PEG is 
particularly known for its protein and cell resistance [362-368], which is believed to be a 
result of its hydrophilicity (hydrophilic molecules stay outside the cell’s plasma 
membrane) as well as the PEG chain length and density [257, 369]. One of the first 
experiments with PEG was performed by Merrill et al. in 1982, showing that the 
adsorption onto glass surfaces prevented adherence of proteins [370]. Ever since, 
various forms of PEG modification became a popular means to render a surface protein 
resistant and to enhance biocompatibility [279]. 
 
1.1.2.4 Timing 
Countless models have been tested thus far to try and prevent the progression to HF 
post-MI. In the search for treatment alternatives, infarcted hearts have been treated with 
different amounts of various cell types, alone or embedded into a range of biomaterials 
or with a variety of biomaterials alone. Although it might be a crucial factor, influencing 
the success of a treatment, the timing of biomaterial injection after a myocardial 
infarction has, to our knowledge, not yet been systematically investigated. In fact, 
across different studies, biomaterials have been injected at various time points, ranging 















That complicates, perhaps even makes it impossible, to compare the outcome of those 
studies and to draw conclusions about their potential as treatment alternative. 
A disadvantage that might relate to delayed injection is the increased difficulty to 
salvage myocardial tissue. Biomaterial delivery immediately after experimental infarct 
induction, on the other hand, might not be able to mimic a clinical setting, as it is much 
more likely that a patient will be treated hours, if not days (if the infarct went 
unrecognized) after a myocardial infarct has occurred. 
 
The following tables (2 a and b) give an overview of a selection of studies that have 


























































Table 2a:  Examples  of s tudies  with  intramyocardial biomater ial  inject ion immediately  post- 
MI  
Immediate biomaterial injection 
 
Group Transplanted material Outcome Reference 
Lin et al.   Self-assembling peptide nanofibers 
were injected with autologous bone 
marrow mononuclear cells 
Improved cell retention 
and post-MI cardiac 
function 
[314] 
Davis et al. Self-assembling peptide nanofibers 
were injected with neonatal 
cardiomyocytes and IGF-1 
Improvement of post-MI 
systolic function 
[316] 
Hsieh et al. Self-assembling peptide nanofibers 
were used for the delivery of PDGF 
Long-term improvement 
of post-MI cardiac 
performance 
[317] 
Segers et al.  Self-assembling peptide nanofibers 
were used for the delivery of SDF-1 
Recruitment of stem cells 
and improved post-MI 
cardiac function 
[319] 
Kofidis et al. Injection of Matrigel with embryonic 
stem cells  
Mice treated with Matrigel 
+ ESCs had superior 
post-MI function relative 
to contro groups 
[230] 
 
Dobner et al. 
 
Injection of a synthetic non-
degradable PEG hydrogel 




Shao et al.  
 
Gelatin hydrogel was used for the 
delivery of bFGF 
Incorporation of bFGF in 
gelatin was superior to 
either of the components 
alone and enhanced 
arteriogenesis and post-
MI cardiac function  
[281] 
 
Ifkovits et al.  Injection of HA 30min post-MI Depending on material 
properties significantly 
increased wall thickness 






















Table 2b: Examples  of MI s tudies  with  delayed intramyocardial biomater ial  inject ion 
  
Delayed biomaterial injection 
 
Group Transplanted material Outcome Reference 
Christman 
et al. 
Fibrin glue and skeletal myoblasts 
were injected one week post-MI 
Preserved infarct wall 
thickness and post-MI 
cardiac function as well 
as increased cell 
transplant survival and 





Fibrin glue-based delivery of 




plasmid efficacy  
[272] 
Dai et al. Collagen injection one week post-MI Thickened infarct scar 
and improved LV function 
[242] 
Landa et al. Calcium-crosslinked alginate was 
injected either one week or two 
months post-MI 
Prevention of adverse 
cardiac remodeling and 
dysfunction in both 
recent and old infarcts 
[241] 
 
Leor et al. 3D alginate scaffold was implanted 




attenuated LV dilatation 
[291] 
 
Yu et al. Injection of either alginate or fibrin glue 
five weeks post-MI 
Increased arteriogenesis 
as well as restoration of 




Huang et al. Comparison of collagen, fibrin and 
Matrigel, injected one week post-MI 
Similar degree of 







hydrogel injected two weeks post-MI 
Increased wall thickness 
and higher capillary 
density relative to saline 
control as well as 


















To our knowledge, so far only two groups injected biomaterials (both alginate) at two 
different time points as part of the same experiment: 
Ruvinov et al. injected immediately as well as six days post-MI. Yet, potential 
differences in outcome were not directly compared. Instead, the rats that were treated 
immediately post-MI were killed one week after the biomaterial injection, while rats, 
which were injected six days after infarct induction were killed four weeks after the 
treatment [293]. Landa and co-workers treated the rats either one week or two months 
after infarct induction, in both groups animals were killed eight weeks after treatment. 
The improvements in old infarcts were less pronounced and hence, Landa suggested 
that earlier injection might achieve a superior effect on the prevention of remodeling, but 
that the optimal timing for implant delivery certainly requires further investigation. Yet, 
the main aim of their study was to demonstrate feasibility rather than primarily 















1.2 Project aims 
Not only are PEG hydrogels considered one of the most inert synthetic biomaterials to 
date [371], they also rank amongst the stiffest mentioned in Wall’s paper [237], who 
had shown that the firmest materials show the greatest benefit for prevention of post-MI 
remodeling. 
As non-degradable PEG hydrogels were shown to elicit an extensive inflammatory 
response after intramyocardial injection, hydrolytically and enzymatically cleavable PEG 
hydrogels need to be characterized in vitro as well as in vivo, with the aim of identifying 
the most compatible degradable PEG hydrogel for intramyocardial injection. 
Secondly, as there is no consensus in the present literature on the timing of biomaterial 
implantation, which currently ranges from minutes to two months post-MI, it needs to 
be investigated if the time point of the biomaterial injection has an influence on the 















1.3 Results and discussion 
1.3.1 Preliminary in vitro characterization of PEG hydrogels 
A study previously conducted in our laboratory, using 20PEG-8VS crosslinked with 
2nPEG-2SH, revealed an extensive macrophage response [244]. The non-degradable 
gel eventually caused scarring and chronic inflammation in uninfarcted myocardium and 
may have also contributed to the loss of an initial functional improvement observed for 
infarcted hearts injected with PEG gel. In an attempt to avoid these adverse effects, the 
focus of the present study was shifted towards the utilization of a degradable PEG 
hydrogel for the treatment of myocardial infarction.  
A selection of degradable PEG gels was investigated to determine the optimal 
composition for myocardial infarction therapy. This is crucial, as the mechanical 
properties of hydrogels largely depend on parameters such as the gelling time, amount 
of swelling, rigidity and degradation rate - all of which are determined by the crosslink 
density [251]. 
The use of a 4-arm crosslinker should polymerize gels faster. There is also the 
possibility they may crosslink macromers more efficiently than 2-arm crosslinkers and 
thus elevate the number of crosslinks obtained. Hence, a hydrogel that is polymerized 
with a 2-arm crosslinker may be “softer” than one with a 4-arm crosslinker, which 
would then be a more rigid gel w th potentially greater strength. Polymers with a low 
crosslink density are preferred for applications, where fast ingrowth and migration of 
cells is needed, while more rigid gels might be favored for mechanically taxing 
environments.  
 
20PEG-8Ac hydrogels were crosslinked with different ratios of 10nPEG-4SH (4-arm 
crosslinker) and 2nPEG-2SH (2-arm crosslinker) and were compared to 20PEG-8VS 
crosslinked using a peptide with MMP-1 recognition site (MMP-1 substrate [MMP-1s]), 
as detailed in chapter 5.1.2. The hydrogels were assessed with respect to the above-
mentioned properties. 20PEG-8VS crosslinked with 2nPEG-2SH was added as non-
degradable control.  
Acrylate-based crosslinks with sulfhydryl are hydrolytically unstable, degrading due to 

















1.3.1.1 Gelling time 
         
                  Table 3:  Gel l ing t imes  
Pre-polymer Crosslinker Gelling time 
100% 4-arm 3’40min 
75% 4-arm, 25% 2-arm 3’00min 
50% 4-arm, 50% 2-arm 3’45min 
25% 4-arm, 75% 2-arm 6’00min 
20PEG-8Ac 
100% 2-arm 9’30min 




          Fig.  3:  Gel l ing t ime (illustrated for 20PEG-8Ac)  
 
 
The gelling time indeed did depend on the number of arms of the crosslinker, as 
demonstrated in Table 3 as well as in Figure 3. Thus, the use of a crosslinker with more 




















1.3.1.2 Swelling  
The first measurement after 24 hours, before any swelling due to degradation could 
occur, showed significantly increased swelling of 20PEG-8Ac crosslinked with PEG-
2SH relative to MMP-1 degradable 20PEG-8VS (p<0.05). According to the Flory-
Rehner Theory, crosslinked polymers absorb solvent, which diffuses into the gel 
network and causes swelling [373, 374]. This is a consequence of positive entropy 
change. The gels do not dissolve but as the volume increases, the network chains are 
stretched and straightened and an elastic retracting force develops. The chain 
deformation causes a decrease in entropy; consequently the swelling process slows 
down. Equilibrium is achieved when the opposing forces are balanced [375]. Network 
chains of gels with higher crosslink density can stretch less and therefore swell to a 
lesser extent.   
Most likely vinyl sulfones react more efficiently with sulfhydryls than acrylate, which 
might explain why the gels swelled less [372]. Thus it appears that vinyl sulfone-based 

















As crosslinks break down, more swelling occurs. Hence, further swelling indicates 
ongoing degradation. The endpoint was observed when the gel eventually became too 
pliable to be handled, i.e. for its weight to be measured. As shown in Figure 4, one of 
the factors that determined the span of time until degradation took place was the type 
of crosslinker the hydrogel was polymerized with. PEGs that were mixed with a 2-arm 
crosslinker took about one month to degrade in vitro, while those crosslinked with a 4-
arm one could be handled for more than 50 days. Thus, hydrogels with a lower 
crosslink density degraded faster because of their increased tendency to swell, which 
resulted in more hydrolytically degradable bonds being exposed to water at a given 
time. Moreover, hydrogels crosslinked with fewer arms de facto have less bonds that 
need to be degraded for the gel to break down. Another aspect influencing the 
degradation was the nature of the macromer: 20PEG-8VS, crosslinked with PEG-2SH 
was non-degradable, while 20PEG-8Ac, irrespective of the crosslinker, would degrade 
by hydrolysis.  
As expected, 20PEG-8VS polymerized with the MMP-1s, which would be cleaved in 
vivo, remained non-degradable in vitro, as the solvent (iPBS) was lacking the MMP-1 
enzyme. Hence, measurements were discontinued on day 60. 
 
As shown in this study, stiffness and degradation of PEG hydrogels can be controlled 
by the choice of macromer and crosslinker. This is a clear advantage synthetically 
derived hydrogels have over natural polymer matrices [251, 255, 279] and one of the 
reasons that justifies the use of PEG in the present study. Moreover, the application of 
synthetic hydrogels eliminates the risk of pathogen transmission and immunogenicity 
[249]. 
 
Another crucial factor is the biocompatibility of hydrogels, relating to the biomaterials 
ability to exist within the body without damaging adjacent cells or eliciting a response 
that impacts on its desired function [251]. Although naturally derived polymers typically 
offer superior biocompatibility to synthetic ones [255, 279], PEG hydrogels are an 
exception from this; due to their hydrophilicity as well as to the PEG chain length and 
density they are known for their protein and cell resistance and hence are often used as 
















Therefore, using a PEG hydrogel allowed the combination of having an engineerable 
biomaterial that typically displays excellent biocompatibility.  
Out of the previously investigated gels (Figure 4), it made most sense to further test the 
“softest” hydrogel that caused most swelling and degraded fastest (hydrolytically 
degradable 20PEG-8Ac crosslinked with 2nPEG-2SH) against the most rigid 
degradable PEG (enzymatically cleavable 20PEG-8VS crosslinked with MMP-1s). Their 
biocompatibility was compared to 20PEG-8VS crosslinked with 2nPEG-2SH, which 
served as non-degradable control.  
 
1.3.2 Subcutaneous assessment of biocompatibility 
The implantation of PEG hydrogel discs underneath the dorsal skin of rats was a 
feasible screening method, as it puts less strain on the animal than an intramyocardial 
injection would, while a larger number of gels could be tested simultaneously. Six gels 
were used per group and three gels were implanted per rat as described in chapter 
5.2.2.2. In a wound healing situation such as this one, the number of monocytes 
typically peaks one to two days after the injury has occurred [376], before they mature 
into macrophages in the wound site. Hence, after four days, the gels together with 
surrounding tissue were explanted, processed and analyzed based on ED1 staining, as 
described in 5.3.1.5. That way, macrophages could be visualized, depicting the extent 
of the inflammatory reaction. 
 
As illustrated in Figure 5, only low levels of macrophage response could be detected 
histologically, with hardly any difference between the three investigated groups. Those 
inconclusive results could perhaps be attributed to subcutaneous implantation not 
being able to offer an accurate reflection of the immune response one would get if one 
was to implant into muscle tissue, which typically has a much better blood supply. 




























Fig. 5: Stitched microscopic images of ED1 s tained PEG hydrogel discs . (A): 20PEG-8Ac 
hydrogel crosslinked with 2nPEG-2SH; (B): 20PEG-8VS crosslinked with MMP-1s; (C): 20PEG-8VS 
crosslinked with 2nPEG-2SH. 


















Although no conclusion could be drawn with respect to biocompatibility, the 
subcutaneous assessment confirmed previous in vitro results. 
As illustrated in Figure 5, after only four days, substantial tissue ingrowth could be seen 
in the 20PEG-8Ac hydrogel crosslinked with 2nPEG-2SH (picture A), in accordance 
with the findings described in chapter 1.3.1. There, the same gel appeared to be the 
“softest”, allowing most swelling to occur and degrading fastest – ideal for tissue 
ingrowth and rapid cell migration. Also consistent with the results in 1.3.1, both 20PEG-
8VS crosslinked with MMP-1s (picture B) as well as crosslinked with 2nPEG-2SH 
(picture C) proved to be rigid gels with high mechanical strength, which hardly swell but 
instead kept their shape. 
 
1.3.3  Intramyocardial evaluation of biocompatibility and time to  
     degradation 
As the non-degradable 20PEG-8VS crosslinked with 2nPEG-2SH had already been 
shown to elicit an extensive macrophage response [244], only the degradable 20PEG-
8Ac crosslinked with 2nPEG-2SH and 20PEG-8VS crosslinked with MMP-1s were 
implanted intramyocardially to gain information about their biocompatibility. 
Furthermore, both hydrogels were evaluated with respect to the time until degradation 
in vivo.  
 
Therefore, rats were operated on as specified in chapter 5.2.2.3. However, for this 
experiment, sham rats were used to avoid confusion of a foreign body reaction with 
inflammation due to a healing infarct. Of the respective hydrogels, 100µl were injected 
per heart. Hearts were explanted four days, one week, two weeks and four weeks after 
hydrogel injection.  
The explants were stained with ED1 (see 5.3.1.5) to assess macrophage response, 
while the explantation at different time points allowed for an assessment of the amount 
of hydrogel left after a certain time and therefore the in vivo degradation rate. Three rats 













                                 
                              20PEG-8Ac crosslinked with 2nPEG-2SH 
       
 
4d post-injection 1w post-injection 2w post-injection 4w post-injection 
 
 
       
                              20PEG-8VS crosslinked with MMP-1s 
 
 
Fig. 6: ED1-based intramyocardial evaluation of biocompatibi l i t y and t ime to degradation. Representative microscopical images of ED1 stained myocardium 
containing PEG hydrogel. Upper row: 20PEG-8Ac crosslinked with 2nPEG-2SH, explanted after: (A) four days, (B) one week, (C) two weeks, (D) four weeks. Lower row: 20PEG-8VS 
crosslinked with MMP-1s, explanted after: (E) four days, (F) one week, (G) two weeks, (H) four weeks. 















                              20PEG-8Ac crosslinked with 2nPEG-2SH 





       
                              20PEG-8VS crosslinked with MMP-1s 
 
 
Fig. 7: Masson’s Tr ichrome-based intramyocardia l evaluation of biocompatibi l i ty and t ime to degradation. Representative microscopical images of MT stained 
myocardium containing PEG hydrogel. Upper row: 20PEG-8Ac crosslinked with 2nPEG-2SH, explanted after: (A) four days, (B) one week, (C) two weeks, (D) four weeks. Lower 
row: 20PEG-8VS crosslinked with MMP-1s, explanted after: (E) four days, (F) one week, (G) two weeks, (H) four weeks. Muscle tissue stained purple, collagen fibers green. Bar 
represents 100µm. 
4d post-injection 1w post-injection 2w post-injection 4w post-injection 















Based on the amount of macrophages that could be seen after ED1 staining, some 
significant differences between the two hydrogels became apparent, as demonstrated 
in Figure 6. Firstly, the immune response elicited by 20PEG-8VS crosslinked with MMP-
1s was considerably milder and more localized than the one caused by 20PEG-8Ac 
crosslinked with 2nPEG-2SH, although both showed evidence of a decline in severity 
over time. Secondly, the inflammatory reaction after injection of 2nPEG-2SH crosslinked 
20PEG-8Ac was widespread and persisted at the injection site throughout the four-
week follow up period although the gel was completely degraded between one and two 
weeks. In contrast, MMP-1 cleavable hydrogels could still be detected after four weeks 
in the myocardium, with almost no immune response left at that time (Figures 6 and 7).  
Encapsulation of an implant by fibrous tissue is a common sign of a foreign body 
reaction, typically demarcating its final stages [356]. Masson’s Trichrome stained 
micrographs showed the appearance of scar tissue around 20PEG-8Ac implants, 
beginning after about two weeks, although the hydrogel was already degraded by then. 
In contrast, throughout that month no scar tissue had formed around MMP-1s 
crosslinked PEG (Figure 7).  
It is possible that the acrylate moiety is more inflammatory than the vinyl sulfone moiety, 
or that the latter reacts more effectively with its crosslinkers, therefore preventing 
unbound, loose ends of the crosslinkers to cause inflammation.  
 
In the search for a degradable PEG hydrogel that is most biocompatible and that can 
provide the infarcted myocardium with adequate mechanical support, MMP-1 
degradable 20PEG-8VS appeared to be the optimal material tested. Additionally, as the 
degradation rate of this hydrogel depends on the migration of cells that secrete MMPs 
(originally to cleave peptide sequences in the fibrin network), it will only disappear at a 
rate that is similar to the new tissue formation. Moreover, MMP-1 degradable PEG 
having a high crosslink density, preventing it from extensive swelling, decreases the 
likelihood of surviving cardiomyocytes being forced apart, lessening their ability to 
generate force effectively. Lastly, the relatively long gelling time of MMP-1 degradable 



















However, before MMP-1s crosslinked PEG hydrogels could be evaluated as treatment 
option after myocardial infarction, adverse effects on the function of healthy hearts 
needed to be excluded. 
 
1.3.4 Effect of MMP-1s crosslinked 20PEG-8VS on the function of   
          healthy hearts 
 
Rats underwent sham operation as detailed in chapter 5.2.2.3 and were then 
randomized to receive an intramyocardial injection of either 100µl MMP-1 degradable 
PEG hydrogel or 100µl of saline as control. At two and four weeks after the injection, 
echocardiography was performed to assess myocardial function as explained in 5.2.3. 
The experiment was terminated after four weeks. 
 
The average fractional shortening (FS) of rats two weeks after intramyocardial saline 
injection was 46.3% (±1.03%) and after injection of 20PEG-8VS crosslinked with MMP-
1 degradable hydrogel 43.02% (±2.58%) (Figure 8) as well as after four weeks 46.5% 
(±0.94%) (saline group) and 44.2% (±2.46%) (hydrogel group) (Figure 9). 
No significant functional difference could be detected between the two groups; neither 

















Fig. 8: Ef fect of intramyocardial hydrogel injection on the function of uninfarcted hearts ,  
14 days after the injection. There was no significant functional difference between injection of saline 
and injection of MMP-1 degradable PEG hydrogel (p=0.26). 
 
Fig. 9: Ef fect of intramyocardial hydrogel injection on the function of uninfarcted hearts ,  
28 days after the injection. No significant functional difference between injection of saline and injection 

















MMP-1 cleavable PEG hydrogel proved to not have any adverse effects on the function 
of healthy hearts. Taking into account its excellent biocompatibility and mechanical 
strength that could help support infarcted myocardium, the feasibility of MMP-1 
degradable PEG hydrogel for myocardial infarct therapy was then tested in a rat infarct 
model. 
 
1.3.5  Investigation of MMP-1 degradable PEG hydrogel for treatment    
           of myocardial infarction  
To assess the value of enzymatically degradable PEG hydrogel for myocardial infarct 
therapy, 100µl of 20PEG-8VS crosslinked with MMP-1s were injected into rat 
myocardium immediately after infarct induction and were compared to the same 
amount of saline as control as detailed in chapter 5.2.2.3. To investigate if the time 
point of a biomaterial application impacts on cardiac function, immediate hydrogel 
injection was directly compared to the same treatment administered after seven days. 
At two and at four weeks post-MI induction cardiac function was assessed with 
echocardiography, before the experiment was terminated four weeks post-MI.  
 
The study was designed as follows: 
 




Infarct induction      Delayed injection Echocardiography Echocardiography 
and immediate        of PEG or saline Heart explant 
injection of  
PEG or saline 
 
 
Aiming to avoid false positive results and to minimize variability between the four 
groups, only rats with a minimum of one eighth of the myocardium being infarcted 
(12.5%) were included in this study. Calculations of the infarct size were based on 
histomorphometric analyses and could therefore only be performed after the hearts 
were explanted. That resulted in an inconsistent number of replicas per group: saline 
delayed injection (n=7), saline immediate injection (n=8), PEG hydrogel delayed injection 















After the infarct size was assessed, echocardiography results of the pertinent rats were 
revealed for analysis.  
 
1.3.5.1 Functional assessment 
Table 4:  Echocardiographic assessment of myocardial function at two and four weeks 
post-MI. ESD: end-systolic diameter in mm; EDD: end-diastolic diameter in mm; FS%: percent of  
fractional shortening 
Weeks Parameter Saline 0d Hydrogel 0d Saline 7d Hydrogel 7d 
ESD   4.9 ± 0.11   5.2 ± 0.21   5.0 ± 0.19   4.3 ± 0.25 * † 
EDD   7.6 ± 0.12   7.8 ± 0.19   7.3 ± 0.16   7.2 ± 0.23 
2 
FS% 34.9 ± 1.28 33.2 ± 1.69 32.0 ± 2.33 39.8 ± 2.05 * † 
ESD   5.2 ± 0.24   5.6 ± 0.25   5.5 ± 0.23   4.7 ± 0.2 * † 
EDD   8.1 ± 0.15   8.4 ± 0.19   8.0 ± 0.19   7.8 ± 0.22 
4 
FS% 35.9 ± 2.41 33.3 ± 1.82 31.9 ± 2.07 40.6 ± 1.36 * † 
*p<0.05 immediate vs. delayed PEG-treatment of infarcted hearts 
†p<0.05 delayed treatment vs. saline control 
 
Fig. 10 : Ef fect of intramyocardial  hydrogel injection on fractional shortening (FS), 14  days 
post-MI. FS after delayed hydrogel injection was significantly improved relative to immediate treatment 















Fig. 11 : Ef fect of intramyocardial  hydrogel injection on fractional shortening (FS), 28  days 
post-MI. FS after delayed hydrogel injection was significantly improved relative to immediate treatment 
and saline control group (p<0.05). 
 
 
Fig. 12 : Ef fect of in tramyocardial  hydrogel  inject ion on end-systol ic diameter  (ESD), 14  
days post-MI. ESD after delayed hydrogel injection was significantly improved relative to immediate 
















Fig. 13 : Ef fect of in tramyocardial  hydrogel  inject ion on end-systol ic diameter  (ESD), 28  
days post-MI.  ESD after delayed injection was significantly improved relative to immediate treatment and 
saline control group (p<0.05).  
 
 
The diameters of PEG hydrogel injected hearts at end-diastole (EDD) were smallest in 
the group that received delayed treated with MMP-1s crosslinked PEG hydrogel at both 
two and four weeks, as outlined in Table 4. However, differences were not statistically 
significant.  
At two weeks post-MI, delayed hydrogel treatment resulted in significantly smaller left-
ventricular end-systolic diameter (ESD) as compared to immediate treatment and saline 
control (p<0.05). Also at four weeks, ESD values were significantly reduced relative to 
both immediate treatment and saline control (p<0.05). 
The group that received the treatment delayed by seven days had significantly higher 
fractional shortening values relative to immediate treatment and saline control (p<0.05) 
after both two and four weeks. 
 
The time point of intramyocardial biomaterial injection indeed had an impact on post-MI 

















1.3.5.2 Infarct size and scar thickness 
The hearts were explanted after four weeks and stained as described in chapter 5.3.1.3 
as well as 5.3.1.4.  
The infarct size was calculated as explained in chapter 5.3.1.8 and, as discussed 
above, only rats with a minimum of one eighth (12.5%) of the myocardial wall being 
infarcted were included in this study. The overall average infarct size amounted to 
20.85% and did not differ significantly between any of the groups (p>0.1). Average 
infarct size after immediate saline injection was 21.8% (±2.54%), after immediate MMP-
1 injection 22.0% (±2.4%), after delayed saline injection 17.7% (±1.94%) and after 
delayed MMP-1 injection 21.9% (±1.68%). 
 
Interestingly, the average scar thickness, calculated as detailed in chapter 5.3.1.8, was 
significantly thicker in the group that received delayed PEG injection compared to 



































                                      
                      
 
Fig. 14 : Scar thickness. Delayed injection of MMP-1 degradable PEG hydrogel resulted in a 
significantly thicker scar. Representative micrographs of MT stained infarcted hearts at four weeks after (A) 
immediate and (B) delayed injection of saline as well as after (C) immediate and (D) delayed treatment with 
20PEG-8VS/MMP-1. Bar represents 1mm (E) Thickness of the infarcted myocardial wall was quantified 
based on histomorphometric analyses. (Chapter 5.3.1.8). Arrows indicate gel deposit. *p<0.05 versus 




















In accordance with functional assessment that showed most improvement after 
delayed biomaterial injection, the thickness of the infarcted scar was only increased in 
the group where the biomaterial was administered after one week.  
 
1.3.5.3 Assessment of hydrogel distribution using Alexa Fluor® 
Micrographs of hearts that were explanted at four weeks after infarct induction 
indicated potential gel deposits that were present after delayed, but not after immediate 
injection, as possible explanation for the observed superior effect of delayed treatment 
(see arrows Figure 14). In order to substantiate that presumption, intramyocardially 
injected MMP-1 degradable hydrogels were visualized by covalent attachment of a far-
red fluorescent label (Alexa Fluor®) as detailed in chapter 5.2.2.3 before injection into 
infarcted rat hearts; either immediately or seven days post-MI. 
 
    
Fig. 15 : Distr ibution pattern of Alexa Fluor ®- label led MMP-1 degradable hydrogel  
immediately after  intramyocardial injection. Injection took place (A) immediately post-MI and (B) 
seven days after infarct induction. 
Nuclei stained blue, hydrogel purple. Bar represents 50µm. 
 
 
Explantation immediately after hydrogel injection revealed completely different 
distribution patterns: hydrogel that was injected with a delay of seven days formed a 
bulky deposit, as opposed to immediately injected PEG, which polymerized in fine 
layers (Figure 15). To investigate if the divergent distribution pattern also had an impact 
on the degradation of the gel, hearts were explanted instantly after immediate post-MI 
injection as well as after three, seven, 14 and 28 days. Following delayed PEG injection, 
three hearts were explanted instantly, as well as two and four weeks after infarct 
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Fig. 16 : Degradation of  MMP-1 cleavable hydrogel , label led with  Alexa Fluor ® .  Immediate injection, explanted after (A) injection (B) three days (C) seven days (D) two 
weeks and delayed injection, explanted after (E) injection (F) two weeks post-MI and (G) four weeks post-MI. Bar represents 500µm. Arrows indicate potential gel deposits. Nuclei 
















Immediately injected gel thereafter completely degraded within two weeks post-MI, 
while hydrogel that was administered with a delay of one week appeared hardly 
changed three weeks after delivery (equals four weeks post-MI) (Figure 16). The bulky 
distribution would be observed throughout the time period. Interestingly, MMP-1 
degradable PEG that was previously injected into uninfarcted hearts was still visible 
after one month (Figure 7), indicating a different degradation rate in healthy 
myocardium. 
 
The difference in degradation rate could be explained, at least in part, by the cardiac 
tissue structure into which the hydrogel gets injected: administering a hydrogel in freshly 
infarcted myocardium that was damaged only a few minutes ago, means injecting into 
a tissue that is still “intact”, as the disruption of structural protein only starts occurring at 
least half an hour after infarct induction [58, 68-70]. That results in the gel “flowing” in 
between cardiomyocyte bundles before it polymerizes. After one week, at the end of 
the necrotic phase [58], the gel most probably gets injected into an edema – which may 
allow for the formation of a bulky deposit. 
 
Being distributed finely, the surface to volume ratio of the immediately injected gel 
would be much larger relative to that of the bulk form of the delayed injections. Hence, 
more of the MMP-1 degradable crosslinks get exposed to enzymatic cleavage, which 
results in a faster degradation. 
 
1.3.5.4 Corrosion casting 
Typically used to reproduce the vascular system of organs or animals, vessels can be 
injected with a plastic polymer that fills the space and rapidly polymerizes.  
Once the surrounding tissue has dissolved with an alkali solution, the cast remains and 
represents the precise structure of the vascular system. Subsequently, the corrosion 
cast can be studied using a scanning electron microscope (SEM), which produces 
images of sample surfaces that have a very high resolution and a large depth of field, 
even capable of revealing details of less than 1nm in size [377]. Since the reagents used 
to form the corrosion cast had a polymerization time that was similar to that of PEG 
hydrogel, this was a suitable method to further investigate by 3D visualization the 
















Rats were infarcted as explained in chapter 5.2.2.3 and randomized to be injected with 
Mercox resin either immediately (n=3) or one week post-MI (n=3). The hearts were 
explanted a few minutes after the respective injection and were treated as described in 
chapter 5.3.3 before the cast was viewed under the SEM.  
Immediately injected corrosion cast polymerized in fine layers in between 
cardiomyocytes, confirming the histological finding of the previous experiment (Figure 
17). It was not possible to retrieve a sufficient amount of delayed injected resin for it to 
be captured on the SEM. A possible explanation for this is that a slightly bigger needle 
was needed to inject the more viscous resin and this may have resulted in the injectate 
leaking out into the ventricle, possibly reflecting the fragility of the infarcted wall at this 
stage of healing. 
 
 
            Fig.  17:  SEM picture of  corrosion cast ,  injected immediately post-MI 
 
1.3.5.5 Assessment of retention of gel within the heart after injection 
Histology indicated a possibly more efficient incorporation of hydrogel after delayed 
injection as opposed to immediate treatment, as shown in Figure 15. Hence, in order to 
quantify the amount of gel at the two investigated time points, the gels were labelled 
with lead. The decision to do so was based on the high affinity of lead for sulfhydryl 
molecules [378] and the high sensitivity and accuracy of ICP-MS (inductively coupled 















The hydrogels were crosslinked with a 4-arm PEG-SH crosslinker to allow for maximum 
loading of lead without substantial disruption of hydrogel structure. The optimal 
concentration of lead loading in the hydrogel was 0.5mM that is equivalent to one lead 
molecule per molecule of PEG-VS. Higher loadings resulted in gels that gelled 
inadequately. A hydrogel loaded at a 1:1 ratio gelled properly in a time equivalent to 
peptide crosslinked hydrogels.  
  
An initial study confirmed that the lead was relatively tightly bound with only 3.3% 
(±0.65%) of lead loaded eluting after incubation of gels in H2O for 24 hours at room 
temperature. After injection of lead labeled gels into excised dead hearts (n=3), 81.8% 
(±0.4%) of lead delivered was recovered after exhaustive tissue hydrolysis. To establish 
a baseline for potential retention of unincorporated lead label, beating hearts in rats 
were injected with an equivalent amount of PEG-SH crosslinker labeled with lead alone 
(n=3). After 30 min, hearts were excised and 5.5% (± 2.6%) of lead loaded remained 
within the heart. Finally infarcted rat hearts were injected with lead labeled hydrogels 
and hearts were again excised 30 min after injection. Only 11.7% (±3.9%) of lead 
loaded remained within the heart. This amount was not significantly more than that 
found in hearts injected with lead labeled crosslinker (p=0.33).  
Thus though it was possible to label PEG hydrogels with lead, in the environment of a 
beating, infarcted heart the label was removed. It is not clear why this displacement 
occurred as these gels certainly gelled within heart tissue. It is possible that a circulating 
thiol containing compound (such as glutathione) may have competed for binding but 
this seems unlikely as in such a scenario it is likely that gel polymerization in general 
would be compromised. Whatever the precise reason for the outcome, it was clear that 
lead labeling was inadequate for the task of assaying differences between gel delivery 
efficiency under variable delivery conditions. The potentially more efficient incorporation 
of gel after delayed injection thus remains an uncorroborated observation. 
 
1.3.5.6 Inflammation 
Another possible explanation for the faster degradation of the immediately injected gel 
was inflammation. Immediately injected gel would not only encounter the naturally 
occurring foreign body reaction, but would also be subjected to a one-week 
















In contrast, hydrogel that gets injected with a one-week delay, when the necrotic phase 
has subsided [58], would be subjected to a shorter period of exposure to additional MI-
induced inflammation. 
 
As illustrated in Figure 18, immediately post-MI injected hydrogel polymerized in fine 
layers in between the cardiomyocyte bundles (A). Since the sample had been explanted 
only a few minutes after the biomaterial application, no inflammatory reaction could be 
detected yet. Three days after immediate PEG injection, macrophages migrated 
towards the foreign body and could be visualized around the hydrogel (B) as well as in 
areas that are remote from the polymer (C). Distant from the hydrogel, neutrophils were 
detected too (C). After one week, the biomaterial was completely surrounded by 
macrophages (D), while neutrophils could, again, only be detected unrelated to the 
hydrogel (E). Two weeks after infarct induction and biomaterial injection, the 
macrophage response persisted (also shown in Figure 6), although remaining small gel 
deposits that might still be present after 14 days (Figure 16) could not be detected (F). 
However, this could be a consequence of the Alexa® signal being impaired by 
immunohistochemistry. One month after immediate injection also the macrophage 
response had subsided (G). 
Injected with a one-week-delay and hence into an edema, PEG gel formed a bulky 
deposit, with single macrophages being visible entrapped within the gel and 
surrounding it (H). Neutrophils were also observed (data not shown). Entrapped 
macrophages could still be seen at the two-week time point but could also be observed 
in the periphery (white arrow) of the gel (I and J). A month after infarct induction and 
therefore three weeks after biomaterial application, the amount of gel appeared to be 
unchanged, causing a moderate immune response in some areas (K) and an intense 
response in other regions (L). However, the stability and integrity of the hydrogel 
structure did not seem to be compromised. 
 
Overall, the predominant response at all time points was macrophage-based, indicative 
of a foreign body reaction to the gel, irrespective whether the gel was injected 
immediately or seven days after infarct induction. Neutrophils could be detected at 
three and seven days, but at much lower levels than macrophages and not associated 















     
 
     
 
     
                         
     
 
Fig. 18: Inf lammatory reaction after immediate and delayed hydrogel injection. Micrographs 
show immediately post-MI injected MMP-1 degradable PEG hydrogel, explanted (A) immediately after 
injection, (B) and (C) after 3d, (D) and (E) after 7d, (F) after 14d and  (G) after 28d. Micrographs of delayed 
injected MMP-1 sensitive PEG hydrogel, explanted (H) immediately after the injection (= seven days post-
MI), (I) and (J) one week after the injection (= two weeks post-MI), (K) and (L) three weeks after the injection 
(= four weeks post-MI). 
Nuclei stained blue, hydrogel purple, macrophages red and neutrophils green. Bar represents 50µm. 
 
 
As shown in the present study, neutrophils typically disappear one week post-MI in rats, 
while macrophages persisted for a greater period of time and associated with 
biomaterial. Based on the time points that were chosen, an earlier neutrophil-based 
attack on the hydrogels cannot be excluded. Evidence suggests that the response to 
the hydrogels was a relatively moderate foreign body-type response for both time 















 1.3.6 Summary  
Remodeling following myocardial infarction has been shown to cause a progressive 
decline in LV performance due to a series of histopathological and structural changes, 
leading to heart failure [55-57] in the majority of infarct patients [164]. The delivery of 
biomaterials (hydrogels) appears to be a promising approach, as first results indicated 
an increased wall/scar thickness [241-244], reduction of adverse LV remodeling [241, 
244, 245], attenuated infarct expansion [246, 247] and improvement of functional 
parameters [241, 242, 247]. 
However, there is no consensus in the present literature on the influence of timing on 
the success of the treatment. Thus, the aim of this investigation was to evaluate MMP-1 
degradable PEG hydrogel in view of its compatibility and to directly compare the effect 
of its injection immediately or seven days post-MI on pathological remodeling. 
Indeed, with this study it could be shown for the first time that the intramyocardial 
injection of MMP-1 cleavable PEG gel is feasible and lead to a retardation of post-MI 
remodeling, if administered with a one-week delay. That conclusion could be drawn 
from the first direct comparison of different time points for treatment administration.  
 
One motivation for choosing PEG hydrogels is their high mechanical strength, which 
makes them ideal for taxing environments such as the beating heart. In fact, according 
to Wall et al., PEG hydrogels are more resilient than naturally derived polymers such as 
collagen, alginate and fibrin and thus rank amongst the stiffest biomaterials [237]. A 
recent study showed that elevated levels of ST2, a marker for biomechanical strain, 
correlates significantly with a higher prevalence of cardiovascular death and heart failure 
post-MI [379]. Hence, increased mechanical stability is desired to provide meaningful 
stress relief for cardiomyocytes [240]. Out of the PEG hydrogels tested in the present 
study, MMP-1s crosslinked PEG proved to swell least, which points towards a high 
crosslink density and therefore a “rigid” gel, which is in good accordance with the 
desire of using a “stiff” material. Another reason for which PEG hydrogels were chosen 
in this experiment, is their bioinert nature [362-368] that made PEGs even become a 
popular means to render a surface protein resistant and to enhance biocompatibility 
[279]. However, a study previously conducted in our laboratory, using non-degradable 
PEG hydrogel, showed an extensive macrophage response, possibly due to the 















Thus, the focus of the study at hand shifted towards the investigation of degradable 
PEG hydrogels, the mechanical properties of which (such as amount of swelling, rigidity 
and time to degradation) can be controlled precisely, while a chronic inflammatory 
reaction can be avoided. The gel with the lowest crosslink density (hydrolytically 
cleavable 2-arm crosslinked PEG) proved to be the one that swelled most and thus 
allowed most rapid tissue ingrowth. It degraded at 30 days in vitro (Figure 4) and two 
weeks in vivo (Figure 7), this difference most likely related to the foreign body reaction 
and the heart being a more taxing environment. The enzymatically degradable MMP-1 
sensitive PEG hydrogel had a much slower degradation rate and appeared to be the 
more rigid gel – ideal for a mechanical taxing environment such as the beating heart. 
Hydrolytically degradable PEG caused an extensive macrophage response when 
injected intramyocardially, which caused scarring in the long run. Enzymatically 
cleavable PEG, on the other hand, only caused a mild and localized immune reaction 
that subsided within a short period of time without resulting in scarring of the 
myocardium. This possibly reflects the acrylate moiety being more pro-inflammatory 
than vinylsulphone. Hence, the investigation of MMP-1 degradable PEG hydrogel as 
biomaterial for intramyocardial post-MI injection was pursued further. 
 
In contrast to other hydrogels such as self-assembling peptides, which can cause 
functional impairment when injected into sham animals [317], MMP-1 cleavable PEG 
injected into uninfarcted rats showed no evidence of adverse effects on myocardial 
performance in the study at hand. Based on that, the value of enzymatically degradable 
PEG for myocardial infarct therapy was evaluated.  
The injection of MMP-1 degradable PEG gel into a one-week-old myocardial infarct was 
effective in ameliorating cardiac performance, as indicated by the fractional shortening, 
a commonly used clinical parameter used for the evaluation of myocardial function. 
Interestingly, although infarct patients commonly benefit from timely intervention [136-
138, 143], delayed treatment was superior to immediate one in this study. 
 
In an attempt to elucidate these results, explanted hearts were analyzed histologically, 
and revealed a significantly thicker scar after delayed injection, relative to immediate 
treatment and to saline control group. When injected after one week, the hydrogel was 
able to prevent wall thinning and to offer mechanical support to the weakened wall, 















These findings were in accordance with the literature, where increased mechanical 
stability results in relief of stress on the remaining healthy cardiomyocytes and 
consequent prevention of heart failure [240, 379]. 
 
To gain a better understanding of the hydrogels geometry that lead to the difference in 
scar thickness, PEG was visualized with the use of a label covalently conjugated to the 
gel. Apart from revealing a well-dispersed distribution pattern after immediate injection 
and the formation of bulky deposits after delayed treatment, the explantation at different 
time points also indicated a much faster degradation of the immediately injected gel. 
That can be explained with a relatively bigger surface area and hence increased 
exposure of enzymatically labile bonds. Understandably, a faster degrading gel resulted 
in less mechanical support to the infarcted wall. The distribution pattern was confirmed 
with the corrosion cast method that, once again, showed fine distribution, the resin 
flowing in between an intact cardiomyocyte structure if administered immediately after 
infarct induction (fibrils of 10-50µm were observed). However, it is not possible to 
comment on the distribution after delayed injection, as most of the resin, being a slightly 
more viscous solution and requiring a bigger needle to be injected, was lost into the 
ventricle or the circulation and could therefore not be assessed. This also indicated the 
fragility of a one-week-old infarcted wall.  
 
Labeling gels with lead and subsequent analysis of its concentration was an attempt to 
quantify the retention of the gel in the myocardium after injection at different time points. 
However, due to removal of the label when injected into a beating heart, the experiment 
failed to provide information about potential differences between immediate and 
delayed injection with respect to the amount of gel left. 
 
Another potential explanation for superior outcome after delayed treatment was 
inflammation, with immediately injected gels being subjected to the inflammatory, 
necrotic phase; in addition to the naturally occurring foreign body response. This theory, 
however, did not provide a clear explanation for the observed differences in degradation 
rates, as the foreign body-type response was very similar for both implant times, with 
macrophages being the predominant response at all time points, while neutrophils were 
observed in both groups at much lower levels than macrophages and not associated 















Instead, evidence indicates that the divergent distribution patterns and surface to 
volume ratio are the most likely explanation for the observed phenomenon. Although 
biomaterials have been injected immediately post-MI [281, 314, 316, 317, 319], after 
one week [234, 235, 242, 272, 274, 291], after two weeks [243] or even after five 
weeks [273], most of these groups neither visualized the distribution pattern of the 
polymer nor did they intend to investigate the impact of timing on functional 
parameters. Other intramyocardially injected polymers very likely behave similarly to the 
MMP-1 degradable PEG used in the present study, as Dobner et al., using a non-
degradable PEG [244] and Ifkovitz et al. injecting Hyaluronic acid [308] showed the 
same fine-layered distribution after immediate administration that has been 
demonstrated in the present study.  
Interestingly, also for intramyocardial stem cell therapy there seems to be a timing 
factor, with early administration (three days post-MI) of bone marrow cells being 
superior to delayed one [380]. Hence, optimal timing might vary between different 
treatment modalities but certainly does influence treatment outcome. 
It is possible that the lower degradation rate of the delayed injected hydrogel is not 
entirely responsible for the functional improvements observed. In a study previously 
conducted in our laboratory, investigating an immediately injected non-degradable PEG 
gel, no functional improvement (as indicated by fractional shortening) could be 
observed [244]. This potentially points towards the different hydrogel structure alone, 
resulting from injections at different time points - not just their degradability - as a crucial 
factor in the reduction of adverse LV remodeling as well as functional improvement. 
Finite element modeling and biomechanical testing to try to determine other possible 
mechanisms behind the observed functional improvement are currently under way.  
 
One has to be careful though when translating results from rats to humans - despite the 
similarities between the rodent and human vascular system [381, 382]. While for animal 
studies a homogeneous group of healthy and young animals without concomitant 
illnesses is being used, cardiac patients with heart failure typically are middle-aged and 
suffer from co-existing diseases [55, 383]. Animals are usually not being treated with 
additional medication, while patients might very well receive simultaneous treatments 

















Even though it may vary between different studies, it is similar for each animal within an 
experiment, while the timing of intervention in clinical trials by necessity fluctuates 
between the included patients. Lastly, infarct sizes in small animals often range from 20 
to even 60% of the LV being ischemic, when in humans 13-16% appear to be a 
“common” interval. 
Nevertheless, for more than 40 years, basic and translational scientists successfully 
used small animal models for cardiovascular research [384], before treatments could be 
applied to larger animals and eventually humans. 
 
The findings of this experiment, which was conducted in a randomized and strictly 
blinded fashion in order to eliminate any subjective bias (see chapter 5.2.2.3 and 5.2.3), 
have practical relevance especially for those myocardial infarct patients, who could not 
benefit from timely treatment initiation. This is particularly the case in patients whose 
infarct went unrecognized due to age, female sex or concomitant diseases such as DM 
[47-49], leading to a time delay of possibly several days before seeking medical 
attention [143]. 
Further research will have to determine if the results found in the present study can be 
translated universally to other intramyocardially injected biomaterials and if their delayed 















2  Utilization of MMP-1 degradable PEG  
 hydrogels for controlled local drug release  
2.1 Introduction  
2.1.1 Corticosteroid administration after myocardial infarction  
Corticosteroids are potent anti-inflammatory, anti-rheumatic and immunosuppressive 
agents that are being used for the treatment of a wide range of disorders such as 
asthma [385], allergic reactions [386] or rheumatoid arthritis [387] - to mention a few.  
In 1953, Johnson et al. were able to show that corticosteroids reduce myocardial infarct 
size in dogs, which was confirmed 20 years later by Libby and colleagues [388, 389]. 
Since then, this group of drugs has been investigated extensively to gain a better 
understanding of their mode of action and to assess their potential value for myocardial 
infarct therapy. 
Corticosteroids act by binding to glucocorticoid receptors, which, in turn, bind to DNA 
sequences, containing glucocorticoid response elements (GRE) and subsequently 
initiate the expression of target genes [390]. Hafezi-Moghadam et al. were able to show 
that this results in the stimulation of phosphatidylinositol 3-kinase (PI3-kinase) and 
protein kinase Akt, a fast activation of eNOS and subsequent NO formation [391]. The 
latter triggers soluble guanylate cyclase (sGC), which mediates a majority of the effects 
of NO, including vasodilation as well as the inhibition of platelet and neutrophil adhesion 
[390]. In view of that, Chen and colleagues injected adenovirus carrying human eNOS 
gene four days prior to coronary occlusion directly into rodent myocardium, which lead 
to inhibition of MAPK signaling and resulted in significantly reduced infarct sizes as well 
as improved contractility one week post-MI [392]. Cardioprotective effects, resulting 
from dexamethasone-induced inactivation of MAPK, could be confirmed by Lochner 
and colleagues [393].  
Investigations have shown that NF-κB activation might play a central role in cardiac 
injury due to intracellular calcium overload [394], resulting in harmful long-term 
















The fact, that corticosteroids augment the expression of annexin1 as well as the 
inhibition of NF-κB might therefore be the basis for another explanation of their 
beneficial effect [390, 395, 396], because the administration of annexin1 diminishes 
both inflammatory response caused by myocardial ischemia as well as infarct size [391, 
397], while the inhibition of activated NF-κB has proven to be cardioprotective [398].  
Furthermore, it could be demonstrated that the application of glucocorticoids results in 
a significantly decreased ischemic area after either permanent coronary artery occlusion 
or after reperfusion [399], possibly due to induction of the cardioprotective heat shock 
protein 72 (HSP72) [400]. Although in another study dexamethasone neither had 
hemodynamic effects in sham operated nor in infarcted animals, the administration of 
the drug resulted in the normalization of elevated ST-segments and prevented the 
increase of Creatine phosphokinase (CPK), an enzyme indicative of muscle damage 
[401].  
 
Various clinical studies were conducted in the 1950’s, -60’s and -70’s, showing 
reduced mortality of infarct patients after corticosteroid administration [402-404]. In one 
study for example, 849 patients with confirmed MI received methylprednisolone, which 
resulted in a significant mortality reduction for patients suffering inferior/posterior 
transmural infarctions [405]. Yet, those positive results couldn’t be confirmed universally 
[406]. Methylprednisolone has been administered in 42 MI patients and has shown no 
beneficial effect two weeks after infarction [407]. Similarly, two high doses of the drug 
were given to 14 patients with MI, while 15 other MI patients served as control group. 
No significant difference could be observed between the two cohorts with regards to 
infarct size (assessed on the basis of serum enzyme levels), arrhythmias, HF or 
mortality. Hence, the authors concluded that the use of corticosteroids post MI has 
neither deleterious nor beneficial effects [408].  
 
Despite all encouraging results, corticosteroids have long been the subject of 
controversy, as some studies were simply not able to confirm their cardioprotective 
property [409, 410]. In fact, their application has even been associated with the 
development of cardiac aneurysms and potentially fatal cardiac ruptures due to 

















Mannisi et al. conducted a study, where rats were treated with either 
methylprednisolone or saline within 24 hours of infarct induction. Infarct sizes were 
similar in both groups but already at three days post-MI, rodents that were treated with 
steroids had a significantly thinner infarct wall thickness relative to the control group 
[412]. That could be attributed to steroids preventing water increase and therefore 
edema, which would naturally reinforce the necrotic infarct against expansion by 
increasing infarct stiffness [58].  
In summary, dyslipidemia and hypertension as well as LV free wall rupture due to 
delayed myocardial scar formation could be identified as the potential main adverse 
effects of corticosteroids on the cardiovascular system [413], which is why their use for 
myocardial infarct therapy has been met with scepticism.  
 
2.1.2 Controlled release of dexamethasone utilizing PEG hydrogels 
One way of avoiding adverse effects of corticosteroids, such as the tendency to thin the 
infarcted wall, potentially even causing cardiac rupture, is to incorporate them into a 
hydrogel, which is able to strengthen the damaged myocardium, while the drug is being 
released.  
Degradable polymeric biomaterials seem t  facilitate the most effective use of agents by 
offering sustained concentrations, i.e. avoiding potentially toxic over-dosing that can 
occur at the beginning of a treatment period and preventing ineffective under-dosing 
that can occur at the end of it [257]. Furthermore, by providing high concentrations of 
the drug only in the local vicinity of the drug-release depot, unwanted concentrations 
distant from the disease site and systemic side effects can be averted, as the slow and 
controlled release would reduce the dose that is encountered by the body at a given 
time. 
 
The incorporation of agents, such as growth factors or drugs can be achieved either by 




















Fig. 19 : Incorporation of drugs. Drugs can be loaded into PEG hydrogels either via in situ entrapment 
or via tethering. For the latter, drugs are being modified with crosslinkable and cleavable tethers and can be 





This concept has already been explored in experimental MI settings, where different 
growth factors were administered together with various biomaterials, the latter serving 
as depot for their sustained delivery [126].  
That way, VEGF a d PDGF, both playing key roles in vessel formation, have 
successfully been delivered to ischemic myocardium [292, 317, 318, 414, 415]. 
Similarly, basic fibroblast growth factor (bFGF) [281], erythropoietin (EPO) [281, 416], 
insulin-like growth factor (IGF-1) [316] and stromal cell-derived factor 1 (SDF-1) have 
been investigated [319] and shown, that the combined delivery of growth factors with 
biomaterials is superior to the injection of free growth factors in saline and may have the 
potential to improve cardiac function post-MI. 
Also Dexamethasone has been incorporated and released from biomaterials, however, 

















2.2 Project aims 
The danger of a possible cardiac rupture still being the number-one-concern, a meta-
analysis conducted in 2003 by Giugliano et al., involving 11 controlled trials with a total 
of 2646 patients, showed that corticosteroid treatment after myocardial infarction was 
associated with a 26% reduction in mortality, while no clear association with myocardial 
rupture could be proven [424]. Hence, it has been suggested to further investigate the 
administration of dexamethasone as part of the treatment of acute coronary syndrome 
[425].   
By incorporating the drug into a hydrogel, the infarcted wall could be stabilized, which 
would prevent possible adverse effects such as the thinning or even rupturing of the 
damaged tissue. Simultaneously, beneficial results such as diminished infarct size or 
reduced post-MI mortality rate could be achieved.  
 
Hence, the aim of this experiment was to incorporate dexamethasone into MMP-1s 
crosslinked and therefore enzymatically degradable PEG hydrogel, comparing both 
entrapment and tethering. It would be interesting to know if the way the drug is loaded 
into the gel as well as its dosage impact on the pace of dexamethasone release in vitro 
and in vivo. Moreover, the effects of controlled, locally delivered dexamethasone, slowly 
















2.3 Results and discussion 
2.3.1 Assessment of in vitro dexamethasone elution 
PEG hydrogels have already been established as controlled release devices, the rate of 
drug elution depending on the method of preparation, the crosslinking density as well 
as drug solubility [325, 342, 426].  
In the present study, dexamethasone was either covalently attached to PEG as detailed 
in chapter 5.4.1 or it was entrapped in the hydrogel as explained in chapter 5.4.2. For 
the latter, dexamethasone was distributed within the gel while it polymerized, so that 
the drug was physically caught in between the polymer network of the PEG. 
Dexamethasone is practically insoluble in water and therefore it precipitates from the 
organic vehicle upon addition to the hydrogel. Due to their size, the precipitates are 
then physically entrapped within the hydrogel, which has porosity dimensions in the 
nanometer range. Its release, however, also depended on the swelling of the hydrogel, 
resulting in stretched and straightened network chains that facilitated dexamethasone 
diffusion. In contrast, the release of the covalently bound steroid was reliant on the 
degradation of ester links that were created between the agent and the polymer 
network of the PEG. Those ester bonds were hydrolytically cleaved by water. Either 
way, if successful polymerization occurred, effective inclusion or coupling of 
dexamethasone to the hydrogel ensued.  
In order to obtain an indication for the rate, at which dexamethasone was going to be 
released from hydrogels in vivo, the elution was initially measured in vitro. As it is very 
difficult to mimic in vitro the cell-driven enzymatic degradation of MMP-1 sensitive 
hydrogels, the two extremes - non-degradable 20PEG-8VS and hydrolytically cleavable 















Fig. 20 : Dexamethasone elut ion from 20PEG-8Ac. (n=3), error bars indiscernible 
 
Fig. 21 : Dexamethasone elut ion from 20PEG-8VS. (n=3) 
 
 
The release of entrapped dexamethasone was compared to its elution when tethered to 
the hydrogel network, investigating both hydrolytically degradable and non-degradable 















For both hydrogels, an initial burst release was observed, most probably related to the 
elution of unbound dexamethasone. The release then protracted, with the covalently 
bound glucocorticoid eluting at a slower pace compared to the entrapped drug, as 
ester bonds had to break down for the steroid to be released. As shown in Figure 20, 
entrapped dexamethasone was eluted from the hydrolytically degradable gel within one 
week, congruent with the pace it was released at from the non-degradable one (Figures 
21 and 22). The elution of the covalently bound drug from the degradable hydrogel took 
12 days to be completed and coincided with the breaking down of the PEG (Figure 20), 
whereas from the non-degradable PEG less than 80% of the covalently bound 
dexamethasone was eluted after 35 days (Figure 21). As the aim was to investigate the 
rate of elution rather than its overall duration, the experiment was discontinued by 
chemical degradation of the PEG (see chapter 5.4.2), which resulted in the release of 
the remaining dexamethasone. 
 While the release of a covalently bound drug from non-degradable PEG solely 
depends on the breaking of ester bonds, its elution from a degradable gel is 
accelerated by the additional degradation of the gel itself, which explains the different 
rate at which dexamethasone was eluted from degradable versus non-degradable 
PEG.   
 
Fig. 22 : Elut ion of entrapped dexamethasone, directly  comparing degradable and non-















The previous study indicated that hydrogel injected immediately after infarction had a 
large surface to volume ratio. As argued below immediate delivery of dexamethasone is 
probably most the most effective approach and thus it was determined whether the 
surface to volume ratio of the hydrogel would have an effect on the rate 
dexamethasone was eluted, gels with a larger surface possibly accelerating drug 
release. Hence, non-degradable PEG gels were formed as droplets and were 
compared to flattened discs, that had been polymerized in between glass slides, thus 
having a surface area to volume ratio that was increased by about 2.5fold.  
Also, it needed to be considered that entrapping different amounts of dexamethasone 
within a PEG gel might have an impact on the rate of agent release, due to potential 
differences in precipitate formation. As detailed in chapter 5.4.2, both droplets and flat 
discs were loaded either with 150µg or with 500µg of dexamethasone. The drug 
release was measured and is illustrated in Figure 23:  
 
Fig. 23 : Dexamethasone elut ion,  comparing dif ferent  dosages and shapes.  (n=3) 
 
Hydrogels carrying a higher dosage of dexamethasone released the drug at a slower 
rate than those that were loaded with a lower dosage. However, an increase in the 
surface to volume ratio of the biomaterial of 2.5fold did not influence the rate at which 
the drug was eluted, and this suggested that the dispersed structure of the injected gel 















Interestingly, gels loaded with a higher dosage released the drug slower than the ones 
with less dexamethasone. This could perhaps be attributed to higher dosages resulting 
in larger precipitates, meaning that the water insoluble drug is entrapped more 
effectively within the polymer network and is therefore eluted at a slower rate – relative 
to the low dosage of dexamethasone. 
Since the dosage as well as the way the agent is attached to the biomaterial does 
influence the rate of its elution, one should be able to precisely control the release of a 
drug into the surrounding tissue, meeting the requirements for biomaterial-based 
medicamentous treatment of cardiac pathologies. 
 
2.3.2 Activity of dexamethasone eluted from PEG hydrogels 
In response to stimulation of glucocorticoid receptors, the cell line MDA-kb2 expresses 
luciferase, which can be quantified to assay dexamethasone activity (detailed in chapter 
5.4.3). Activity of released dexamethasone, entrapped in both degradable and non-
degradable hydrogel as well as the drug, covalently bound to both degradable and 
non-degradable PEG gel was measured (Figures 24 and 25). 
 















Fig. 25 : Activi ty  of dexamethasone elu ted from non-degradable 20PEG-8VS. (n=3) 
 
 
Activity of eluted dexamethasone was demonstrated for both degradable and non-
degradable PEG hydrogels. Due to an initial burst release of the entrapped drug, the 
total amount of dexamethasone did drop off, as the eluate was replaced at every time 
point. Consequently also the activity of entrapped dexamethasone declined, while the 
activity of the covalently bound agent was sustained for a longer period of time (Figures 
24 and 25). 
 
2.3.3 In vivo evaluation of dexamethasone release from PEG hydrogels 
Even though the results in this thesis demonstrate that delayed biomaterial 
administration is superior to immediate hydrogel injection after myocardial infarction, 
that concept had to be re-evaluated when it came to the combined treatment with 
glucocorticoids.  
The influence of post-MI steroid treatment on LV remodeling and inflammation have 
been investigated previously, using different time points of administration [427]. 
Methylprednisolone was either given early (from time of MI to 24 hours post-MI) or late 

















Indeed the timing of treatment had an impact on the outcome: administration of 
methylprednisolone within the first 24 hours after infarct induction increased MMP 
activity, which contributed to the break down of structural proteins. However, these 
effects did not translate into major changes in LV structure and function. In contrast, 
hearts that were exposed to late methylprednisolone treatment showed significant 
augmentation of MMP activity, which resulted in adverse effects on global and scar LV 
structure as well as cardiac performance. Moreover, potentially beneficial effects of 
steroids, such as diminished infarct size [388, 389] as well as cardiovascular protective 
effects [391] can only be achieved by timely administration, before the infarct can 
expand and before cardiomyocytes get irreversibly damaged.  
Hence, myocardial infarction was induced in rats as detailed in chapter 5.4.4. Animals 
were randomized to receive one of the following six treatments immediately post-MI: 
150µg covalently attached dexamethasone, 150µg or 500µg dexamethasone 
entrapped in MMP-1 cleavable PEG hydrogel, 150µg or 500µg applied without the gel 
(free dexamethasone) and saline as control. Administering 150µg dexamethasone 
translated to 0.75mg/kg, the dosage of 500µg equ led 2.5mg/kg. For evaluation of the 
amount of dexamethasone that was eluted from PEG hydrogels, blood samples were 
taken from the tail vein, starting at two hours post-MI, followed by collections every 24h 
for up to ten days after infarct induction (section 5.4.4). 
 
2.3.3.1 In vivo elution of dexamethasone  
All rats included in this study (together with the ones belonging to the saline control 
group) showed an initial weight loss that persisted for three days, which can most likely 
be attributed to common post-operative effects, such as analgesia-related decreased 
food and water intake. Saline-treated rats lost significantly less body weight within the 
first three days post-operatively (-5.5%±1.25%) than rats treated with 500µg free 
dexamethasone (-16.36%±2.12%, p≤0.05) and substantially less than rats that were 
treated with 500µg entrapped dexamethasone (-11.5% ± 1.79%, p<0.1). 















Fig. 26 : Postoperati ve weight development of rats  with MI  
 
Interestingly, throughout the first week, rats that belonged to the saline control group 
gained significantly more weight (+6.8%±2.1%), relative to rats that were treated with 
500µg free dexamethasone (-3.8%±1.17%, p<0.05) or 500µg entrapped 
dexamethasone (-0.3%±1.2%, p<0.05). As this is most likely a consequence of the 
catabolic effect of steroids, the weight loss was an in vivo confirmation of the activity of 
the drug throughout the first week.  
 
Quantitative analyses of blood samples were unable to confirm this release of 
dexamethasone. Despite the sensitivity of the LC-MS/MS assay (chapter 5.4.5), which 
can easily detect concentrations down to 100ng/ml, and although slow drug release 
and activity had previously been proven in vitro, it was not possible to detect the 
dexamethasone in the blood. 
One explanation could be a burst release, which is not uncommon in vivo. Studies of 
VEGF eluted from calcium-alginate microspheres revealed an uncontrolled elution within 
the first four days [428]. Those release kinetics are typically seen with hydrogel-type 
delivery systems, such as the release of 70-100% of growth factors initially added to 
















The same applies to PEG hydrogels, the high water content of which is critical in 
maintaining the bioactivity of hydrophilic biomolecules [430]. As a result, a rapid release 
takes place, not only shortening the efficacy of the delivery device, but also causing a 
“dose-dumping” effect that is potentially detrimental for the surrounding tissue [342].  
In a pharmacokinetics study of dexamethasone in a rat model of rheumatoid arthritis, 
healthy and arthritic animals were given either a low (0.225mg/kg) or a high (2.25mg/kg) 
intramuscular dose, in order to determine if the inflammation process alters distribution 
and clearance of the drug [431]. Dexamethasone absorption from the intramuscular site 
was rapid, reaching a maximum concentration after 0.5h for all doses, with hardly any 
difference between the plasma concentration of dexamethasone between healthy and 
arthritic rats. The measurements of plasma levels in the study at hand only commenced 
two hours after dexamethasone was administered, which is why the peak plasma 
concentration might have been missed. However, Earp at al. were able to detect 
dexamethasone for about 24 hours after intramuscular injection [431], while in the 
present study not even covalently bound dexamethasone could be quantified. This 
phenomenon could perhaps be explained with the covalently attached drug being 
eluted too slowly, which resulted in plasma concentration levels that might have been 
too low to be detectable. It is also possible that the pharmacokinetic methodology 
utilized needed optimization, as in vitro hydrolysis after sample collection occurs at a 
much faster rate in rat plasma (in vitro half life 1.75h) than in does in plasma of sheep or 
humans (in vitro half life ten to 12h) [432]. 
Further analysis of the hearts from the rats included in this study (see below) argued 
against further effort and expense being directed towards investigating the drug 
analysis methodology. Although the study was mainly designed to investigate the 
release rates of dexamethasone in vivo, it also allowed observing cardiac performance 
as well as scarring thickness. 
 
2.3.3.2 Cardiac function 
Cardiac function was assessed three weeks post-MI. To reduce variability and to avoid 
false positive results, a minimum of one eighth (12.5%) of the LV had to be infarcted for 


















Fractional shortening (FS) of the saline-treated group amounted to 35.9% (±2.41%); 
free dexamethasone (150µg) 33.3% (±2.88%); free dexamethasone (500µg) 36.7% 
(±4.39%), entrapped dexamethasone (150µg) 31.2% (±1.89%), entrapped 
dexamethasone (500µg) 35.1% (±2.85%) and bound dexamethasone (150µg): 33.0% 
(±2.15%). No significant difference was found between any of the groups (p>0.1). 
Therefore, the post-MI use of corticosteroids had neither deleterious nor beneficial 
effects on cardiac performance. 
 
2.3.3.3 Histological findings 
To assess if dexamethasone has a thinning effect on infarct tissue, potentially 
contributing to the previously described complication of infarct rupture [58, 411, 412], 
rats were killed after three weeks and their hearts investigated histologically.  
As mentioned before, a minimum of 12.5% of the LV had to be infarcted for rats to be 
included in this study. The overall average infarct size amounted to 24.6% (±1.97%). 
Average infarct size after treatment with saline was 21.8% (±2.54%), free 
dexamethasone (150µg): 28.0% (±5.24%), free dexamethasone (500µg): 18% 
(±2.31%), entrapped dexamethasone (150µg): 21.3% (±3.9%), entrapped 
dexamethasone (500µg): 27.3% (±10.7%) and bound dexamethasone (150µg): 26.2% 
(±3.22%). There was no significant difference between any of the groups (p>0.1). 
Including all rats that were treated with dexamethasone in this study (n=16), the 
average scar thickness was 1.005mm (±0.03mm). As previously stated, this study was 
initially designed to investigate pharmacokinetics of biomaterial-based dexamethasone 
release, which is the reason for the small number of replicas per group (free 
dexamethasone (150µg): n=4, free dexamethasone (500µg): n=3, entrapped 
dexamethasone (150µg): n=3, entrapped dexamethasone (500µg): n=2, bound 
dexamethasone (150µg): n=4) and only two rats that were injected with saline as 
control. Being sufficient for a pharmacokinetics study, the size of the saline control 
group was not adequate for statistically meaningful histomorphometric analyses. 
Therefore, measurements of saline control hearts from previously conducted, larger 
studies were used as comparison, as the animals were tightly age and sex matched. 
According to Holmes et al., the fibrotic phase (i.e. collagen deposition) in rats is 
completed two weeks post-MI [58]. In accordance with that, the scar thickness of rats 
















Thus, the average scar thickness of dexamethasone-treated rats three weeks after 
infarct induction (1.005mm ± 0.03mm) was analyzed against the average scar 
thickness of saline-treated rats from previously conducted studies (1.215mm ± 
0.08mm) and was found to be significantly thinner (p<0.05) (Figure 27).  
 
Fig. 27: Average scar thickness of infarcted rat hearts. Animals were treated either with saline (as 




As there was no definitive proof of an increased risk of myocardial rupture related to 
post-MI corticosteroid treatment in a meta-analysis involving 2646 patients, but 
evidence of a substantial reduction in mortality [424], the investigation of 
dexamethasone for treatment of acute coronary syndrome has been suggested 
previously [425]. Incorporating the steroid into a hydrogel would prevent possible 
adverse effects such as thinning of infarcted tissue, while at the same time beneficial 
effects such as diminished infarct size [388, 389] and reduced post-MI mortality rate 

















The delivery of the agent together with a non-degradable macromer, polymerized with 
enzymatically degradable crosslinkers, should allow a controlled slow tissue dependent 
release of the appended molecules. Hence, the aim of this experiment was to 
incorporate dexamethasone into MMP-1s crosslinked and therefore degradable PEG 
hydrogels, comparing the effect of both entrapped and tethered drug on functional and 
histological parameters.  
 
In the study at hand, it could be demonstrated that the attachment of a drug to an 
enzymatically cleavable PEG hydrogel is a feasible method, allowing the precise control 
of drug elution in vitro by using different attachment methods as well as varying 
dosages. 
 
Steroids have been shown to cause a thinning of infarcted tissue, which was confirmed 
in the present study and which could not be prevented by the simultaneous 
administration with PEG hydrogels. That can, at least in part, be explained with MMP-1 
sensitive PEG hydrogels being unable to improve scar thickness if injected immediately 
after an infarct has occurred, as shown in this thesis for the first time. Delayed injection, 
however, would not have been beneficial either, as reduction in infarct size and 
cardioprotection need to be achieved before infarct expansion can take place or 
cardiomyocytes suffer irreversible damage. Moreover, it has been shown previously that 
delayed steroid treatment had adverse effects on post-MI remodeling [427]. 
 
This randomized and blinded study was conducted to investigate whether one could 
take advantage of the beneficial properties of dexamethasone, whilst avoiding its 
adverse effects when injected together with an enzymatically degradable PEG hydrogel. 
The findings, however, showed that post-MI steroid administration, despite the 
simultaneous delivery with a hydrogel, lead to significant thinning of the infarcted wall.  
Although a sustained release was proven in vitro, the results could not be confirmed in 
vivo, as the dexamethasone was not detectable in the blood samples. This is difficult to 
explain, particularly for the covalently bound agent. 
As dexamethasone administration did not result in any functional improvement, but 
rather contributed to an increased post-MI scar thinning, no further investigations 
towards potential explanations were pursued. These present findings are further 















3  Determining the ability of PEG hydrogels  
 with tethered dexamethasone to prolong  
 transduced cardiac gene expression when 
delivered in conjunction with an adenovirus  
 
3.1 Introduction  
3.1.1 Adenoviral vectors for gene therapy  
Gene therapy is a rapidly growing area of research that has the promise to treat many 
genetic and acquired diseases. The use of viruses’ natural ability - to infect a host and 
introduce “foreign” genome into the host’s cells - is a powerful tool. Thus a variety of 
different viruses are being explored for this purpose [433]. 
 
Despite the induction of potent host immune responses and a limited duration of 
transgene expression [434, 435], adenoviral vectors have received significant interest as 
a potential delivery vehicle [436-443]. They are medium-sized viruses (90-100nm) that 
mainly cause upper respiratory, eye and intestinal diseases and have a genome that 
consists of linear, non-segmented double-stranded DNA. After infection, adenoviral 
DNA does not integrate into the genome of the host cell and is therefore not replicated 
during cell division. The use of adenoviruses has shown some promising results for a 
variety of applications [444-446], the focus now being the treatment of cancer [447-
458]. The frequent use of adenoviruses can be attributed to the non-pathogenicity for 
their host, the relatively easy production of high-concentration viral stocks, the high 
transduction efficiency and ability to transduce both proliferating and quiescent cells 
[459, 460]. 
An important factor that needs to be taken into account is that the transduction of cells 
with therapeutic genes naturally causes an immune response. Since this limits the 
efficacy and, most importantly, the safety of viral gene therapy [461], adequate 
immunosuppression has to be administered. In this context, the adenovirus is a suitable 















3.1.2 Modulation of immune response through combined delivery with  
    dexamethasone 
Generally, it is much more difficult to control an already established immune response 
as opposed to implementing prevention strategies, before it even has a chance to 
develop [462].  
Prophylactic strategies include the design of vectors in such way that they contain only 
few (or ideally no) pathogenic genes [463], the use of tissue specific promoters to 
ensure localized “action”, restricted to the target tissue [464], the regulated expression 
of the transgene [465, 466] or alternatively the use of drug-induced 
immunosuppression, the latter being a very well established strategy for organ 
transplantation [462].  
Although being a promising approach, some possible adverse effects need to be 
considered: possible hindrance of transduction efficacy and vector stability, drug side 
effects that could aggravate underlying metabolic complications and increased 
susceptibility to infection by opportunistic pathogens [462, 467]. The risk of activating 
latent infections can be reduced though by monitoring drug levels and by aiming for a 
short overall duration of immunosuppression [462].  
 
A new protocol, involving a single dose of dexamethasone, was established lately, 
showing diminished innate and adaptive immune responses, while at the same time 
avoiding adenovirus stimulated thrombocytopenia and leukocyte infiltration [468]. As 
dexamethasone has also already been established to attenuate foreign body reactions 
of the tissue around implants [417-422], it would make sense to couple gene therapy 
















3.2 Project aims 
Having developed polyethylene glycol (PEG) hydrogels that can polymerize 
spontaneously in vivo to allow for controlled release of dexamethasone; it is possible 
that these dexamethasone-loaded gels have the potential to reduce the inflammatory 
and immune responses to viral vectors.  
 
Hence, the aim of this study was to investigate the efficacy of these types of PEG 
hydrogels in sustaining gene expression and reducing inflammation in cardiac cells after 
in vivo transduction with adenovirus. 
As an initial investigation in this area, the impact of the simultaneous delivery of 
dexamethasone containing PEG gel with adenovirus vector carrying the GFP gene on 
















3.3 Results and discussion 
In order to assess the ability of slow release dexamethasone hydrogels to sustain green 
fluorescent protein (GFP) expression by adenovirus-infected cardiac cells and to reduce 
the inflammatory and immune response towards these cells, dexamethasone was 
successfully modified by acrylation, solubilized by PEGylation and covalently 
incorporated into PEG gels as detailed in chapter 5.5.1. A rat model that allowed for the 
assessment of the immune and inflammatory response to intramyocardially injected viral 
vectors and their transgenes was used as detailed in chapter 5.5.2. 
The gels were crosslinked in situ via MMP-1s that allowed for enzymatic degradation 
over one to two weeks. The dexamethasone was released in its original form by 
hydrolysis over that period. The rats were killed after one week and assessed for GFP 
expression, cardiac tissue damage, macrophage and T-lymphocyte content. 
 
3.3.1 Quantification of GFP expressing cells and tissue damage 
As demonstrated in Figure 28, the total area of cells expressing GFP in the 
dexamethasone group was substantially higher than in the control hydrogel group 
(Virus/hydrogel: 60000µm2 ± 36000µm2, Virus/dexamethasone hydrogel 467000µm2 ± 
113000µm2 (n=5), with a 7.7fold greater area of cells expressing GFP (p≤0.05). 
There was substantial tissue damage in both groups with no significant difference 
between the two groups (Virus/hydrogel: 11859000µm2 ± 401000µm2, 




























     
 
     
 
Fig. 28: Area of cel ls expressing GFP. (A) AdV + PEG hydrogel, (B) AdV + PEG hydrogel + 150µg 
dexamethasone. Upper row: bar represents 1mm, lower row: bar represents 100µm. Both groups were 
injected with a total of 100µl PEG, containing 1x109 pfu AdHCN4. (C) Quantitative analysis, p≤0.05. Nuclei: 
blue, GFP expression: green  

















        
 
 
Fig. 29 : Tissue damage H&E stain of (A) AdV + PEG hydrogel, (B) AdV + PEG hydrogel + 150µg 
dexamethasone. Bar represents 1mm. Both groups were injected with 100µl PEG, containing 1x109 pfu 




The area of tissue damage was substantially larger than that of GFP expressing cells, 
indicating that 2.8% of GFP expressing cells were left at one week for the 
dexamethasone group whilst only 0.5% for the control group had survived. Tissue 
damage was spread through a larger volume of myocardial tissue.  
 















3.3.2 Inflammatory and immune response  
A similar trend was observed for the macrophage and T-lymphocyte responses (Figures 
30 and 31), with both groups having similar levels of inflammation and immune 
responses. Image analysis results led to analogous findings (Macrophage: 
Virus/hydrogel: 1317000µm2 ± 906000µm2, Virus/dexamethasone hydrogel 
1886000µm2 ± 639000µm2; T-lymphocyte: Virus/hydrogel: 1196000µm2 ± 371000µm2, 
Virus/dexamethasone hydrogel 1102000µm2 ± 142000µm2). 
 





Fig. 30 : Macrophage response (A) virus + PEG hydrogel, (B) virus + PEG hydrogel + 150µg 
dexamethasone. (ED1 staining) Bar represents 500µm. Both groups were injection with 100µl PEG, 
containing 1x109 pfu AdHCN4. (C) Area of macrophages relative to GFP Expression, p=0.6.  
 

















     
 
Fig. 31: T- lymphocyte response (A) virus + PEG hydrogel, (B) virus + PEG hydrogel + 150µg 
dexamethasone. (CD3 staining), Bar represents 500µm. Both groups were injected with 100µl, containing 




While the area of cells expressing GFP was substantially higher in the dexamethasone 
group, no decrease in tissue damage or inflammation was observed. 
Although the difference was significant, data comparison between area of tissue 
damaged and GFP expressing area indicates that only a small number of cells were 
rescued. Additionally, it is possible that by looking at only one time point that there may 
have been an initial decrease in the inflammatory response but that this stage was 
missed. 
 















There is literature showing that dexamethasone activates protective signaling pathways 
in cardiomyocytes [388-391, 393, 399, 401], but it is less easy to see how this might be 
protective for transduced cardiomyocytes that are targeted by the immune system. 
 
3.3.3 Summary 
A newly established protocol, involving pretreatment with dexamethasone, showed 
diminished innate and adaptive immune responses towards adenoviral vectors, without 
reducing their efficacy [468]. Hence, the present study was carried out to determine the 
efficacy of dexamethasone-releasing PEG hydrogels in prolonging GFP expression by 
reducing immune and inflammatory response to adenovirus.  
The outcome of the present study indicates that local delivery of a ti-inflammatory 
drugs show promise for  prolonging cardiac cell expression after transduction with an 
adenovirus vector. This outcome was most likely achieved through reduction of the 
immune and inflammatory response but this could not be confirmed due to only one 
time point being observed. It was beyond the scope of this thesis to extend the number 
of time points observed. However, only a small number of cells could be rescued, 
which is not surprising taking into account that dexamethasone alone might not be 
potent enough to accomplish a meaningful reduction of immune-mediated loss of 
vector persistence. Hence, Wang et al. administered a cocktail of immunosuppressive 
drugs to achieve sustained AAV-mediated gene expression in a canine model [469]. In 
view of that, it is advantageous that the chemistry of these gels can be further refined to 
allow for release of other anti-inflammatory and immunosuppressant agents to enhance 















4 Conclusions  
Post-infarct remodeling has been shown to cause impaired cardiac function due to 
complex changes in ventricular architecture, eventually leading to heart failure in many 
patients, who suffered a heart attack. Hence, cardiac failure has become an important 
therapeutic target, with the delivery of biomaterials (hydrogels) being one possible 
option that can result in increased wall/scar thickness, lessening of adverse LV 
remodeling as well as attenuated infarct expansion and improvement of functional 
parameters. Divergent timing regimes of previously conducted studies make it difficult 
to evaluate the outcome of the treatment, thus the present study is the first to directly 
compare immediate injection and biomaterial delivery delayed by seven days. The 
injection of MMP-1 degradable PEG gel into a one-week-old myocardial infarct was 
feasible and effective in ameliorating cardiac performance. Interestingly, although infarct 
patients commonly benefit from timely intervention, delayed treatment was superior to 
immediate one in this study. Histological analysis revealed a significantly thicker scar 
after delayed injection, relative to immediate treatment and to saline control group. 
Evidence indicates that the divergent distribution patterns and surface to volume ratio 
are the most likely explanation for the observed phenomenon. The findings of this 
experiment have practical relevance especially for those myocardial infarct patients, 
who could not benefit from timely treatment initiation.  
 
In a second experiment, the value of steroid releasing PEG hydrogels for the treatment 
of myocardial infarction was investigated. Incorporating dexamethasone into a hydrogel 
would prevent possible adverse effects of the agent, such as thinning of infarcted 
tissue, while at the same time beneficial effects of steroids, such as diminished infarct 
size and reduced post-MI mortality rate might be achieved through the controlled slow 
tissue dependent release of the appended molecules. It could be demonstrated In the 
present study that the attachment of a drug to an enzymatically cleavable PEG hydrogel 
is a feasible method, allowing the precise control of drug elution in vitro by using 
different attachment methods as well as varying dosages. Although a sustained release 
was proven in vitro, the results could not be confirmed in vivo, as dexamethasone was 















Moreover, the present study confirmed the previously demonstrated thinning effect 
steroids have on infarcted tissue, which could not even be prevented by the 
simultaneous administration with PEG hydrogels. This can, at least in part, be explained 
with MMP-1 sensitive PEG hydrogels being unable to improve scar thickness if injected 
immediately after an infarct has occurred, as shown in this thesis for the first time. 
Delayed injection, however, would not have been beneficial either since reduction in 
infarct size and cardioprotection need to be achieved before infarct expansion can take 
place or cardiomyocytes suffer irreversible damage. These present findings are further 
evidence that the use of steroids may not be advisable for post-MI treatment.  
 
A newly established protocol, involving pretreatment with dexamethasone, showed 
diminished innate and adaptive immune responses towards adenoviral vectors, without 
reducing their efficacy. Hence, a third set of experiments was carried out to determine 
the efficacy of dexamethasone-releasing PEG hydrogels in prolonging GFP expression 
by reducing immune and inflammatory response to adenovirus. Proof of principle for 
drug releasing PEG gels to aid in sustained gene expression via viral vector delivery for 
the treatment of pathologies of the heart could be demonstrated in the present study 
and might have resulted from a reduction of the immune/inflammatory response. The 
outcome was suggestive that prolonged duration of expression was obtained with a 
7.7fold increase in GFP expression at one week for those viruses that were injected 
with hydrogel releasing dexamethasone relative to those injected with hydrogel alone.  
 
In the thesis at hand, MMP-1 degradable PEG hydrogels proved to be helpful in 
ameliorating post-MI cardiac function, with delayed intramyocardial injection being 
superior to immediate treatment. Furthermore, proof of principle for biomaterial-based 
drug release could be demonstrated, which could aid in applications such as sustained 















5 Materials and methods 
5.1 In vitro preparation and preliminary experiments 
5.1.1 Polyethylene glycol derivatisation 
As per Lutolf et al., 20PEG-8VS was synthesized in dry Dichloromethane (DCM) by first 
deprotonating 20PEG-8OH with sodium hydride (NaH) followed addition of a large 
excess of divinylsulphone (C4H6O2S). The remaining NaH in the crude reaction mixture 
was quenched by acetic acid (CH3COOH) prior work-up through three consecutive 
precipitations in ether [338]. According to Elbert et al., 20PEG-8Ac was synthesized in 
dry DCM by adding Acryloyl chloride (C3H3ClO) to 20PEG-8OH in presence of base 
(Triethylamine, TEA) in a dry environment. The crude reaction mixture was worked up 
by three consecutive precipitations in ether [470]. The following crosslinkers were 
acquired by purchase: 2kDa non-degradable dithiolated Polyethylene glycol (2nPEG-
2SH), 10kDa non-degradable tetrathiolated Polyethylene glycol (10nPEG-4SH) and 
matrix metalloproteinase-1 substrate (MMP-1s). All polymers were stored at -20°C. 
Iso-osmotic Phosphate buffered saline (iPBS), which was utilized as solvent for the 
polymers, was prepared as follows (Table 5):  
 
 Table 5 : Content  iso-osmotic PBS solut ion 
Solution Components 
1      2.07g   
100.0ml     
NaH2PO4.1H2O  
Distilled water 




3    8.766g    




95ml NaH2PO4.1H2O solution was mixed with 415ml Na2HPO4.12H2O solution, to which 
508ml of solution 3 were added. This resulted in an iso-osmotic buffer with a pH of 7.6. 
















5.1.2 Preliminary in vitro characterization of PEG hydrogels    
Gels of 10% (m/v) nominal concentration were prepared by dissolving 10mg 20PEG-
8Ac in 50µl iPBS and adding 50µl of a crosslinker solution. For the latter, 2-arm and 4-
arm crosslinker solutions were prepared in five different ratios:  
o 100% 10nPEG-4SH (10mg in 50µl iPBS)  
o 75% 10nPEG-4SH (7.5mg in 37.5µl iPBS) + 25% 2nPEG-2SH (1mg in 12.5µl 
iPBS) 
o 50% 10nPEG-4SH (5mg in 25µl iPBS) + 50% 2nPEG-2SH (2mg in 25µl iPBS) 
o 25% 10nPEG-4SH (2.5mg in 12.5µl iPBS) + 75% 2nPEG-2SH (3mg in 37.5µl 
iPBS) 
o 100% 2nPEG-2SH (4mg in 50µl iPBS) 
  
Those hydrogels were compared to 10mg 20PEG-8VS in 50µl iPBS crosslinked with 
4mg 2nPEG-2SH in 50µl iPBS and 10mg 20PEG-8VS in 25µl iPBS crosslinked with 
3.45mg MMP-1s in 75µl iPBS.  
 
For each of the seven groups, three discs with a total volume of 100µl were 
manufactured and then incubated in iPBS at 37°C. The gelling time was recorded and 
their weight was measured at set time points until the gels were degraded. 
 
5.2 In vivo evaluation of degradable PEG hydrogels 
5.2.1 Animals 
Male outbreed Wistar rats (180-220g) were used for the in vivo studies. Animals were 
bred and housed at the Animal Unit, Faculty of Health Sciences, University of Cape 
Town for at least five to six weeks before the start of the experiments. Five to six 
animals were kept in each cage (Eurostandard Type IV, 595 x 380 x 200mm, floor area 
1820cm2) at constant room temperature (21-23°C). The rats were exposed to a 12h 
light/dark cycle (6am-6pm) and had free access to water and food (Rat & Mice Feed 
16%). Wood shavings served as bedding and shredded paper was supplied for 
environmental enrichment. 
Rats that were used for experiments testing the feasibility of cardiac delivery of viral 















The handling and all animal experiments complied with the Principles of Laboratory 
Animal Sciences [471] as well as The UFAW Handbook on the Care and Management 
of Laboratory Animals [472] and were approved by the Animal Research Ethics 
Committee, Faculty of Health Sciences, University of Cape Town. 
 
5.2.2 Surgical procedures 
5.2.2.1 Pre-surgical preparation  
Surgical procedures were carried out under aseptic conditions. The same instruments 
were used for five to ten animals, but were sterilized between operations in the Hot 
bead sterilizer. 
 
Placed into the induction chamber and sedated with 5.0% Isoflurane at an oxygen 
output of 1.5l/min at 1bar and 21°C, the animal became unconscious within 
approximately two minutes. The rat was temporarily removed from the chamber for its 
weight to be measured and to shave off the fur from chest or dorsal skin. 
 
5.2.2.2 Subcutaneous implantation  
In preparation, discs consisting of 20PEG-8Ac crosslinked with 2nPEG-2SH, 20PEG-
8VS crosslinked with MMP-1s as well as 20PEG-8VS crosslinked with 2nPEG-2SH 
were polymerized in between glass slides to ensure a thickness of 1.0mm and a 
diameter of about 0.8cm. Six gels were produced for every group, each having a total 
volume of 50µl. 
The unconscious rat was transferred to the heated operating board and connected to 
the Rodent Anesthesia Circuit Mask, which supplied 2.0% Isoflurane at an oxygen 
output of 0.3l/min at 1bar and 21°C. After disinfection of the dorsal skin, up to six 
longitudinal incisions of 1.0cm each (up to three on either side of the spine) were made 
with a disposable blade. Gentle spreading of subcutaneous and connective tissue 
allowed the creation of subcutaneous pouches, so that one round pre-manufactured 
flexible PEG disc could be implanted into each pocket. A rotational algorithm was used 
for the implantation of the discs, so that the position of each group varied from animal 

















5.2.2.3 Myocardial infarct model  
For airway protection and to provide a means of mechanical ventilation, the rat had to 
be intubated, which was carried out according to Theodorsson et al. (2005) [473]:   
The animal was secured in a supine position on the Tilting WorkStand, the head 
directed towards the operator, using the Incisor Loop to hold the neck extended. With 
cotton swabs the rats tongue was rolled out and held up, while the Rat Specula, which 
was connected to an otoscope, was inserted for visualization of the vocal cords. A 16G 
i.v. catheter (57mm) was gently slid down the Rat ET Tube Introducer, between and 
past the vocal cords, until the hub reached the incisors. After removal of the metal 
guide wire, the tracheal intubation was verified with a dental mirror. Before the animal 
could regain consciousness, it was attached to the Harvard Small A imal Ventilator, 
supplying 2.0% Isoflurane at an oxygen output of 0.3l/min at 1bar and 21°C and at a 
respiratory rate of 115 breaths per minute. The correct connection to the ventilator was 
visually confirmed when the rhythmic movements of the rats chest were in synchrony 
with the ventilator. 
 
Surgical procedures were performed according to modified protocols from Tarnavski et 
al. and Huang et al. [474, 475]: 
Being connected to the ventilator, the animal was placed in supine position onto the 
heated operating board. The limbs were fixed to the platform; chest and abdomen were 
thoroughly cleaned. Using a disposable blade, an approximately 2cm transverse skin 
incision was made along the 4th intercostal space to expose the underlying 
subcutaneous tissue. Pectoral muscles were separated with sterilized cotton buds and 
gently retracted with a pair of sutures (2-0 non-absorbable polyester), which were fixed 
onto the platform with tape. To expose the heart, the chest cavity was opened at the 4th 
intercostal space by bluntly dissecting the intercostal muscles with a hemostat, taking 
extreme care not to damage the underlying lung. That allowed the retractor to be 
inserted to spread the ribs apart. Using two forceps, the pericardial sac was gently torn, 
providing better exposure of the heart and improving the visualization of big vessels like 
the LAD (left anterior descending) coronary artery, which appeared as a bright red 
spike. However, contrary to what is widely stated in literature, the LAD was not always 
clearly visible. Then, a 6-0 non-absorbable Polypropylene ligature was placed under the 
















Discolorations of the anterior wall of the left ventricle from pink to grey and reduced 
contractility were hallmarks of a successful occlusion of the artery. 
Once the artery was ligated, the animals were randomly assigned to receive one of the 
following three materials, injected either immediately after infarct induction or in a 
second operation seven days post-MI: 
 
1) Injection of Alexa Fluor labelled PEG hydrogel 
Per 100µl gel, 1µl of 10mg/ml Alexa Fluor® 660 C2 maleimide in dimethyl sulfoxide 
(DMSO) was added to 1µl of 15.4mg/10ml dithiothreitol (DTT) in iso-osmotic 
phosphate-buffered saline (iPBS, pH 7.6) and reacted for 30min at 37ºC. One microliter 
of the above Alexa/DTT solution was added to the 20PEG-8VS solution (10mg in 25µl 
iPBS) and reacted for 10min at room temperature before being mixed with the MMP-1 
solution (3.45mg in 75µl iPBS). 100µl of the hydrogel were aspirated into a BD Micro-
Fine + Demi syringe and injected into the myocardium before the two components 
polymerized. The successful application resulted in a slight swelling of the respective 
area, indicating that the hydrogel did not escape into the left ventricular cavity. 100µl 
saline served as control. 
 
2) Injection of lead 
Alternatively, 100µl 20PEG-8VS hydrogel crosslinked with 2nPEG-2SH and labelled 
with lead, as described in chapter 5.3.2, were injected into the infarcted area. 
 
3) Injection of Mercox resin 
The casting material consists of two components: a resin (Mercox) and a catalyst 
(Benzoyl Peroxide 40%). Here, 1ml of Red Mercox resin was mixed with 20mg of 
catalyst just before 100µl of it were injected into the infarcted myocardium as the 
polymerization takes place in a relatively short period of time.  
 
After the removal of the retractor, 4-0 silk was used to draw the rib cage together, 
taking care not to suture the lung. While tying a knot, slight pressure was applied on the 
chest to reduce the volume of free air in the cavity. The wound was stepwise closed 
and the skin was sutured with 4-0 silk before finally being cleaned with iodine solution. 
















5.2.2.4 Postoperative care 
As soon as spontaneous breathing was regained, 0.05mg/kg buprenorphine 
(Temgesic®) was administered intramuscularly into the hind limb. Being transferred to a 
single, clean cage (Eurostandard Type III H, 425 x 266 x 185mm - floor area 800cm2), 
rats was allowed to recover, while heat was provided for about 45min by an infrared 
lamp in order to maintain the animals body temperature. Intubated rats were kept with 
the intubation tube placed in the trachea until they regained full consciousness. In 1h 
after surgery the animals should be completely awake and move around in the cage 
and were then provided with water and food ad libitum. 
All rats underwent postoperative control by staff of the Animal Unit. Top-up doses of 
buprenorphine were administered twice daily for three days post-operatively. 
 
5.2.3 Echocardiography 
To evaluate cardiac function in a serial and noninvasive manner, transthoracic 
echocardiography was performed according to Collins et al. [476] on days 14 and 28 
post-MI, in a blinded fashion to eliminate subjective bias. The key that identified the 
animals and which group they belonged to was kept by a third party and was not 
revealed to the examiner before all data had been recorded and analyzed.  
 
5.2.3.1 Sedation 
In order to ensure precise image acquisition during cardiac ultrasound, the animal had 
to be sedated. Generally, most anesthetics have a negative inotropic and chronotropic 
effect and consequently alter cardiac function significantly. However, the impact of 
various intraperitoneal and inhaled anesthetic agents on echocardiographic parameters 
had been compared in mice, concluding that Isoflurane resulted in the most stable 
fractional shortening values and the most reproducible measurements [477].  
Thus, the rat was placed into the induction chamber and anaesthetized with 5% 
Isoflurane at an oxygen output of 1.5l/min at 1bar and 21°C for the first 2min, while for 
the maintenance 1.5% Isoflurane were supplied at an oxygen output of 0.3l/min at 1bar 
and 21°C via the Rodent Anesthesia Circuit Mask. The animal was placed in left lateral 
position onto the operating board after the fur was shaved off chest and abdomen. 
















To further minimize adverse effects on cardiac function the operating board was heated 
to avoid anesthesia-induced hypothermia and consecutive decrease of heart rate and 
cardiac output [478] and care was taken not to place excessive pressure on the chest 
with the transducer as this could result in bradycardia and hypotension; lastly a short 
overall time of anesthesia was aimed for.  
 
5.2.3.2 2D and M-mode 
The parasternal long axis, for which the transducer was directed towards the right 
shoulder of the animal, gave a first impression of LV size and function. After a 90º 
clockwise rotation at papillary muscle level, the parasternal short axis could be viewed 
and was used for 2D- and M-mode derived measurements, according to the 
Recommendations for quantitation of the left ventricle by two-dimensional 
echocardiography [479].  
At the time of apparent maximal dilation of the left ventricle, the left ventricular end-
diastolic diameter (LVEDD) was measured, whereas the left ventricular end-systolic 
diameter (LVESD) was obtained at the time of visible maximal left ventricular 
contraction. Based on those values, the fractional shortening (FS) was calculated using 
the following formula (Equation 2):  
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Eq. 2: Calculation of Fractional shortening (FS) 
 
To reduce variability between measurements, in both 2D and M-mode imaging, left- 
ventricular end-diastolic diameter and left-ventricular end-systolic diameter were 
measured six times and their mean was calculated thereafter. 
 
5.2.4 Termination of in vivo experiments 
For further analysis of the in vivo experiments, animals had to be killed at selected time 



















For histological studies, explants were fixed in a 4% paraformaldehyde solution, which 
was prepared by dissolving 4.0g paraformaldehyde powder (95%) in 90ml iPBS. The 
mixture was heated to 60°C, cleared with five to ten drops of 10M sodium hydroxide 
(NaOH) and adjusted to a pH of 7.0-7.5 using hydrochloric acid (HCl). Fresh iPBS was 
added to obtain a total volume of 100ml.  
 
5.2.4.2 Explantation of subcutaneously positioned PEG discs 
Using Halothane, the animal was made unconscious before being killed by an 
intracardiac injection of Euthapent. PEG discs as well as surrounding subcutaneous 
tissue were excised and explants were fixed at room temperature in the 4% 
paraformaldehyde solution for a 24h period.  
 
5.2.4.3 Harvesting the heart (myocardial infarct model) 
After making the animal unconscious as described above, it was placed in supine 
position. Following a cutaneous incision from the abdomen towards the sternum, an 
intramuscular incision along the rib cage was made. By carefully lifting up the rib cage, 
the apex of the heart became visible through the diaphragm and was arrested with 1ml 
of ice-cold saturated potassium chloride (KCl) solution, injected directly into the 
myocardium. The organ was carefully harvested, thoroughly rinsed with 0.9% sodium 
chloride (NaCl) solution and fixed in the 4% paraformaldehyde solution for 24h.  
 
5.3 Post-mortem analysis 
5.3.1 Histology and image processing 
5.3.1.1 Embedding of subcutaneously positioned PEG discs  
After 24h fixation in 4% paraformaldehyde, the sample was kept in a 70% alcohol 
solution for about 1-2h. This was followed by infiltration of tissue for 48h in a mixture of 
100ml JB-4™ Solution A and 0.9g of JB-4™ Catalyst. For the embedding process, 1ml 
of JB-4™ Solution B was dissolved in 25ml of fresh catalyzed JB-4™ Solution A, which 
was then added to the tissue that was placed in a mould and kept under anaerobic 
















Sections of the tissue, varying between 2µm and 3µm of thickness, were cut on the 
Microm tissue microtome HM 360, using an 8mm glass knife. Samples were floated on 
a 60°C water bath (Tissue Floating Bath TFB 45), which contained one drop of 
saturated NaOH solution, helping them to spread out evenly. The sections were then 
picked up on glass slides, baked on a hot plate (Axel Johnson Lab System HP-3) and 
were placed for 2-3min in running tap water prior to being stained with either 
Haematoxylin & Eosin (H&E) or ED1. 
 
5.3.1.2 Embedding of hearts (myocardial infarct model) 
After 24h fixation in 4% paraformaldehyde, the rat heart was cut in four equal slices 
using a disposable blade and was dyed with different colours to disti guish between 
the sections. The Tissue-Tek® Rotary Tissue Processor was used to process the 
sections overnight and included the following solutions (each for 1h): 70% alcohol, 80% 
alcohol, 96% alcohol, three baths of 100% alcohol, three baths of xylene and three wax 
baths. After processing, tissues were embedded in paraffin wax (Histosec® Pastillen) 
with the Shandon Histocentre 2 embedder. The sections were then cut, having a slice 
thickness of 3µm for further staining with Haematoxylin & Eosin, Masson Trichrome or 
ED1 or 8µm for DAPI staining. Sections were floated on the 60°C water bath, picked up 
on glass slides and baked on the hot plate for 10min at 60°C. Finally, the tissues were 
dewaxed through three baths of xylene (10min each), agitated in three baths of 
absolute alcohol and hydrated for approximately 5min in running tap water. 
 
5.3.1.3 Haematoxylin & Eosin staining 
Mayer’s Haematoxylin and alcoholic EosinY/Phloxine B solutions were used for routine 
























Table 6 : Protocol Mayer’s Haematoxyl in 
 Components Procedure 
1 
 
   1g Haematoxylin 
 50g Aluminium potassium sulfate 
        (AlK(SO4)2) 
0.2g Sodium iodate (NaIO3) 
Dissolve in 1000ml distilled water 
using gentle heat (water bath or 
37°C incubator) 
2  50g Chloral hydrate (C2H3Cl3O2) 
   1g Citric acid (C6H8O7) 
Add to the mixture and dissolve  
well     
3  Boil for 5min, cool and filter the  
mixture 
 
Table 7 : Protocol alcohol ic  EosinY/Phloxine B solution 
 Components Procedure 
1 
 
  10ml   1% Phloxine B           
100ml   1% Eosin Y              
780ml 95% Alcohol 
Mix 
2     4ml         Glacial acetic acid     
                  (CH3COOH) 
Add to the mixture  
 
 
Sections were placed in Mayer’s Haematoxylin for 5-10min and were then washed for 
5-10min in running tap water to blue the nuclei of the cells. In order to stain the 
cytoplasm, the slides were placed for 1min in the 1% alcoholic EosinY/Phloxine B 
solution.  
Resin-embedded sections were air-dried but not mounted, whereas samples, which 
were embedded in wax, were washed in running tap water, dehydrated through three 
baths of absolute alcohol, cleared in three baths of xylene and were mounted with 
Entellan®.  
As the result, the nuclei stained blue, cytoplasm and all other tissue components 
appeared in varying shades of pink. In comparison to healthy myocardium, infarcted 



















5.3.1.4 Modified Masson’s Trichrome staining 
Masson’s Trichrome stain was used for a differential demonstration of muscle and 
collagen fibers. It typically involves three dyes, one being a nuclear stain. However, in 
this context a modified technique was employed, which did not include the nuclear 
staining. 
Slides were placed for 30min in Bouin’s Fluid (post fixative) in order to enhance the 
Masson’s Trichrome stain (Table 8):  
 
 Table 8 : Content  Bouin ’s  Fluid 
Amount Component 
  75ml Picric acid solution (saturated  
aqueous) 
  25ml Formaldehyde (35-40%)  
             5ml Glacial acetic acid 
 
Sections were then washed in running tap water until clear. A 0.5% Acid Fuchsin 
solution (Table 9) was applied to the slides or 5min, which was followed by rinsing in 
tap water.  
 
 Table 9 : Content  Acid Fuchsin 
Amount Component 
   0.5g Acid Fuchsin 
    0.5ml Glacial acetic acid  
        100.0ml Distilled water (pH 7.4) 
      
 
In order to remove excess Acid Fuchsin, the sections were treated with 1% 
Phosphomolybdic acid solution for 5min. The slides were washed in tap water and 
counterstained for 2min with 2% Light Green SF Yellowish. Sections were then 
dehydrated through three baths of absolute alcohol, cleared in three baths of xylene 

















5.3.1.5 ED1 & Neutrophil Elastase Double Fluorescent staining   
Slides were antigen retrieved with Proteinase K at 37°C for 10min (15min if the sections 
were embedded in resin), which was followed by washing in running tap water for 5min. 
After being washed with Tris-buffered saline (TBS, Table 10) for 5min, the sections were 
treated with 1% Bovine serum albumin (BSA) for 20min in order to prevent background 
staining. The 1% BSA solution was prepared by mixing 1g of BSA with 100ml of iPBS.  
TBS contained the following: 
 
 Table 10 : Content  TBS 
Amount Component 
30.3g Trizma® hydrochloride 
6.95g Tris base (Tris hydroxymethyl  
amino methane)  
     43.83g NaCl 
  5.0l Distilled water ( H 7.6-7.8) 
 
      
The primary antibody was applied as a cocktail of two antibodies: monoclonal ED1 
mouse anti rat CD68 (diluted 1:50 in BSA for resin-embedded sections and 1:100 for 
wax embedded ones) and polyclonal Neutrophil Elastase (diluted 1:200 in BSA) for 1h 
at room temperature. Thereafter, they were washed with TBS for 10min. Secondary 
antibodies were applied as a cocktail: Donkey Anti-Mouse Cy3 (diluted 1:2000 in BSA 
for resin-embedded slides and 1:500 in wax-embedded ones) and Alexa Fluor® 488 
goat anti-rabbit IgG (diluted 1:50 in BSA) for 2h in the dark at room temperature to 
prevent the light from interfering with the staining. Finally, the sections were washed 
with TBS for 5min, coverslipped with VECTASHIELD® and sealed with commercially 
available nail polish (to prevent dehydration) before they were stored in the fridge.  
The staining resulted in fluorescent red macrophages and blue nuclei.   
 
5.3.1.6 DAPI staining 
The sections were washed in TBS and were mounted with VECTASHIELD®, which 
contains DAPI, a fluorescent stain that binds strongly to DNA, thus visualizing the nuclei 















Meanwhile the PEG hydrogel distribution within the myocardium was demonstrated by 
detecting the covalently bound Alexa fluor 660 maleimide marker using the Cy5 filter on 
the microscope. Nuclei appeared blue, while the PEG gel had a pink color.   
 
5.3.1.7 Image acquisition   
Images of the tissue were acquired with the Eclipse 90i Microscope (X-Cite® 120 
Fluorescence Illumination System) and were captured with the Nikon Digital Camera 
DXM-1200C. That was connected to a PC with the NIS-Elements BR 2.30 Software to 
view the pictures. Slides that were used for measurements of infarct size and scar 
thickness were viewed on the Eclipse E1000M Microscope and captured with the 
Nikon Digital Camera DXM-1200, using a 0.5x magnification lens.   
 
5.3.1.8 Measurements of infarct size and scar thickness 
Both infarct size and scar thickness were calculated based on quantitative 
histomorphometric analyses of Masson Trichrome-stained slides. The data was derived 
from midline length measurements of all four sections of the heart according to 
Takagawa et al. [480].  
Thus, the left ventricular myocardial midline was drawn at the centre between the 
epicardial and endocardial surfaces, using the VIS - Visiopharm Integrator Systems. The 
length of the midline was measured as midline circumference. The section of the 
midline, where the infarct took up more than 50% of the whole thickness of the 
myocardial wall was defined as midline infarct length. Dividing the sum of midline infarct 
lengths of all four sections by the sum of midline circumferences of all four sections and 
multiplying that by 100 determined the infarct size. 
Measurements of the scar thickness were taken in 1mm intervals within the area in 
which the scar took up more than 50% of the thickness of the myocardial wall. The 
values were added and divided by the number of measurements in order to calculate 
the average thickness of the scar. Measurements of both the infarct size as well as the 



















5.3.2 Quantification of lead 
5.3.2.1 Attachment of lead to PEG hydrogels  
For lead acetate loaded gels that were 10% (m/v) concentration, 40µl 10nPEG-4SH 
solution (250 mg/ml in Hepes) was incubated with 4.8µl lead acetate solution (40mg/ml 
in H2O) for 60 minutes at 25°C. After incubation, 40µl 20PEG-8VS solution (250 mg/ml 
in Hepes) was added and the volume adjusted to 100µl. Gels were placed in 5ml H2O 
and aliquots taken at selected times to determine binding of lead within the PEG gels. 
 
5.3.2.2 Analysis of lead extraction from the hearts  
Excised hearts were lyophilized for one day. The dried hearts were then placed in 10ml 
of a solution containing equal parts of nitric acid and hydrogen peroxide and shaken at 
100rpm at 37°C for 24 hours in a closed 50ml Falcon tube. Subsequently the hearts 
were incubated at 60°C for two days until complete hydrolysis of the heart was 
observed and a clear pale yellow liquid obtained. Lead content of samples was assayed 
on an XSeries II ICP-MS. Samples were diluted 100 times using a "lab" solution (5% 
HNO3 in which were added four internal standards - Bi, In, Re, Rh at a concentration of 
10ppb). Calibration of the instrument was done with three standards made from artificial 
standard solutions. 
 
5.3.3 Visualization of corrosion cast 
The explanted hearts were treated with 10% KOH, then rinsed, dried, coated with gold 
and observed under a scanning electron microscope (SEM). 
 
5.4  Utilization of MMP-1 degradable PEG hydrogels for    
       controlled local drug release  
5.4.1 Incorporation of dexamethasone into PEG hydrogels  
Dexamethasone was dissolved in Tetrahydrofurane (THF, 5mmol in 200ml), mixed with 
10mmol TEA and acryloyl chloride (C3H3ClO, 10mmol) was dropwise added. The 
solution was allowed to react overnight at room temperature before being purified by 

















Pegylated dexamethasone (dexPEG) was manufactured by adding the acrylated 
dexamethasone (dexAc, 10mg in 200µl ethanol) dropwise to 2nPEG-2SH solution (45mg 
in 300µl iPBS), while stirring. The reaction proceeded for 24 hours at 37°C and more 
ethanol was added to achieve a final ethanol concentration of 80%. Unreacted dexAc 
was removed by two consecutive precipitations in 15ml cold ether, centrifugation and 
drying.  
 
5.4.2 Dexamethasone elution  
For covalently bound dexamethasone, 10mg 20PEG-8VS (non-degradable) or 
alternatively 10mg 20PEG-8Ac (degradable) in 50µl iPBS were crosslinked with 3.2mg 
2nPEG-2SH in 25µl iPBS and 1.78mg dexPEG in 25µl iPBS. PEG hydrogels with trapped 
dexamethasone were produced by crosslinking 10mg 20PEG-8VS or alternatively 
20PEG-8Ac dissolved in 50µl iPBS with 4mg 2nPEG-2SH in 25µl iPBS and adding 
0.150mg dexamethasone in 25µl iPBS. The solutions were vortex-mixed and three 
discs per group, each with a total volume of 100µl, were formed. Once prepolymer and 
crosslinker had polymerized completely, the hydrogel discs were incubated at 37°C in 
individual tubes, filled with 500µl iPBS.  
At set time points, the eluate of each sample was removed and replaced with fresh 
iPBS.  
UV absorbance of dexamethasone was measured on the UV-1601PC 
spectrophotometer at 241.8nm and was used to calculate the amount of 






                     
! 
m = 44.056   
                                                                                    (m = slope of calibration curve) 
                                
 mass (of dex released from gel) = conc (of dex in the eluate) x volume (of eluate) 
 
                        

















Chemical degradation of PEG was achieved by adding sodium hydroxide to the 
hydrogels. 
The eluates of these four groups were also used to confirm the activity of 
dexamethasone as described under 5.4.3. 
In a second experiment, the influence of different dexamethasone dosages as well as 
varying surface areas of the hydrogels on the rate of drug elution was tested. Two 
groups were compared: 10mg 20PEG-8VS in 50µl iPBS crosslinked with 4mg 2dPEG-
2SH in 25µl iPBS and 0.5mg dexamethasone in 25µl iPBS added as well as 10mg 
20PEG-8VS in 50µl iPBS crosslinked with 4mg 2dPEG-2SH in 25µl iPBS and 0.150mg 
dexamethasone in 25µl iPBS added. 
After the solutions were vortex mixed, discs with a total volume of 100µl were formed. 
Three gels of each group were shaped as droplets, three were compressed in between 
two glass slides during polymerization to increase their surface area. The hydrogel discs 
were incubated at 37ºC in individual tubes, each containing 500µl iPBS. 
Dexamethasone elution was measured as described above.  
 
5.4.3 Activity of dexamethasone eluted from PEG hydrogels  
The human mammary gland cell line MDA-kb2, sourced from the American Type 
Culture Collection (ATCC) was used to determine the activity of dexamethasone, which 
was eluted from the discs into the iPBS.  
MDA-kb2 expresses firefly luciferase under control of the MMTV (mouse mammary 
tumor virus) promoter that contains response elements for both glucocorticoid 
receptors (GR) and androgen receptors (AR). Luciferase was subsequently quantified 
with the ONE-Glo™ Luciferase Assay System. Using a 96-well Cell Culture Plate, each 
well contained 104 MDA-kb2 cells and 100µl Leibovitz medium. After 4h medium was 
replaced by 90µl fresh medium plus 10µl of the eluate and then incubated overnight. 
100µl of the reconstituted ONE-Glo™ reagent (one bottle of ONE-Glo™ Buffer 
thoroughly mixed with one bottle of ONE-Glo™ Substrate) was added and the 
luminescence was measured using the Veritas Microplate Luminometer.  
 
The dexamethasone activity was expressed as a fold increase, normalized to eluates 
















5.4.4 In vivo assessment 
For in vivo assessment of dexamethasone elution from PEG hydrogels, animals were 
operated on as described under 5.2.2.3 and 5.2.2.4. However, immediately after infarct 
induction, animals were randomized to receive 100µl of one of the following solutions, 
to be injected into the infarcted myocardium:  
4µl dexamethasone150 solution (37.5µg dexamethasone in 1µl DMSO) in 96µl iPBS; 4µl 
dexamethasone500 solution (125µg dexamethasone in 1µl DMSO) in 96µl iPBS; 10mg 
20PEG-8VS in 25µl iPBS crosslinked with 3.45mg MMP-1s in 75µl iPBS and 4µl 4µl 
dexamethasone150 solution; 10mg 20PEG-8VS in 25µl iPBS crosslinked with 3.45mg 
MMP-1s in 75µl iPBS and 4µl dexamethasone500 solution; 10mg 20PEG-8VS in 50µl 
iPBS crosslinked with 3.2mg 2nPEG-2SH in 25µl iPBS and 1.78mg dexPEG in 25µl iPBS 
as well as saline as control. 
To evaluate the amount of dexamethasone that was eluted from the PEG hydrogels, 
blood samples were taken from the tail vein, starting at 2h post-MI, followed by 
collections every 24h. After the samples were spun for 15min at 3200rpm and 4°C, the 
plasma was stored at -20°C for subsequent analyses. 
Cardiac function was assessed using echocardiography before the animals were killed 
for histological and histomorphometric analyses of the explanted hearts as described 
under 5.2.3 and 5.3.1.  
 
5.4.5 Dexamethasone quantification 
Blood samples were analyzed using a liquid chromatographic tandem mass 
spectrometric (LC-MS/MS) assay. 
The samples were processed with a protein precipitation extraction method, using 50µl 
plasma and 150µl acetonitrile. The internal standard used, was 4-androstene-3,17-
dione, and was spiked into the precipitation solvent at a concentration of 200ng/ml.  
The plasma samples with the precipitation solvent were vortex mixed for 1min, ultra-
sonicated for 5min, and centrifuged at 13000 rpm for 5min.  A 100µl of the supernatant 
was transferred to a 96 well plate and 10µl was injected onto the HPLC column. 
Gradient chromatography was performed on a Gemini-NX analytical column, using 

















An AB Sciex API 3200 mass spectrometer was operated at unit resolution in the 
multiple reaction monitoring (MRM) mode, monitoring the transition of the protonated 
molecular ions at m/z 393.3 to the product ions at m/z 355.3 for dexamethasone, and 
also monitoring the protonated molecular ions at m/z 287.3 to the product ions at m/z 
97.1 for the internal standard. The accuracies (%Nom) for the dexamethasone 
calibration standards were between 95.6% and 102.7%. The precision (%CV) for the 
dexamethasone calibration standards was between 0.3% and 14.5% for the entire 
calibration range. The calibration range used for sample analysis was between 
78.0ng/ml and 1250ng/ml.   
 
5.5  Determining the ability of PEG hydrogels with tethered  
       dexamethasone to prolong cardiac gene expression when  
       delivered in conjunction with adenovirus  
        
5.5.1 In vitro preparation 
To test whether PEG hydrogels can be used to advance viral vector delivery, Adv-
AcGFP-HCN4t-M2-final, provided by Medtronic, Inc., was incorporated into a 10% 
20PEG-8VS hydrogel, crosslinked with MMP-1s (total volume of 100µl), to be injected 
intramyocardially with and without dexamethasone. The dexamethasone content was 
150µg and was the acrylated form that covalently attached to the hydrogel via a 
hydrolytically degradable linkage.   
 
5.5.2 In vivo procedure 
Ten rats were operated on as described in chapter 5.2.2.3 and 5.2.2.4, however no 
myocardial infarction was induced. After pericardiotomy the rats were randomized to 
receive 1.5x109pfu of either Adv preparation, hence there were five replicates per 
group. The experiment was terminated after one week as described in chapter 5.2.4 
 
5.5.3 Analysis  
Image analysis was carried out on stitched images derived from the Nikon 90i using the 
analysis software Visiopharm.  
For analysis of GFP, the entire cross section was captured where GFP expression was 















For macrophages and T-lymphocytes, the intensity of the fluorescent label did not allow 
for the use of low magnification objectives and thus the microscope was unable to 
stitch entire cross sections. Therefore a blinded observer captured 3.2mm2 (3x3 fields) 
representative regions. The software identified all fluorescent cells accurately and 
precisely.  
 
5.6 Statistical analyses 
Animal studies were randomized and blinded. Comparison between the groups was 
made by means of 1-way ANOVA (STATISTICA), followed by Fisher’s PLSD test. 


















5.7 Reagents and equipment 
Table 11 : Reagents   
Product Producer Product No. 
Acetonitrile 
LiChrosolv® 
Merck kGaA  
Darmstadt, Germany 
100029 
Acid Fuchsin Merck KGaA 
Darmstadt, Germany 
105231 





Alexa Fluor 660  
C2-maleimide 
Invitrogen Molecular Probes  
Eugene, Oregon, USA 
A-20343 
Alexa Fluor® 488  
goat anti-rabbit IgG 
Invitrogen Molecular Probes  
Eugene, Oregon, USA 
A-11034 
Aluminum potassium  
sulfate (AlK(SO4)2) 
Saarchem  
Merck Chemicals (Pty) Ltd  
Gauteng, South Africa 
SAAR1118000EM 
4-Androstene-3,17-dione Sigma-Aldrich® Chemie GmbH 
Steinheim, Germany 
A9630 
Bovine serum albumin  
(BSA), IgG-Free,  
Protease-Free 
Jackson ImmunoResearch  
Laboratories, Inc. 
West Grove, PA, USA 
001-000-162 
Chloral hydrate  
(C2H3Cl3O2) 
Saarchem  
Merck Chemicals (Pty) Ltd  
Gauteng, South Africa 
SAAR1591500EM 
Citric acid (C6H8O7) Saarchem  
Merck Chemicals (Pty) Ltd  

































Product Producer Product No. 
Dimethyl sulfoxide  
(DMSO) 
Sigma-Aldrich® Chemie GmbH 
Steinheim, Germany 
D2650 
Dithiothreitol (DTT)  Sigma-Aldrich® Chemie GmbH 
Steinheim, Germany 
D9779 
Divinyl sulfone  
(C4H6O2S) 
Sigma-Aldrich® Chemie GmbH 
Steinheim, Germany 
V3700 
Donkey Anti-Mouse IgG  
(H+L), Cy3 
Jackson ImmunoResearch  
Laboratories, Inc. 
West Grove, PA, USA 
715-166-151 
ED1 mouse anti rat  





Entellan® Merck KGaA                            
Darmstadt, Germany 
107961 
Eosin Y BDH Ltd. 
Poole, UK 
341972Q 
Euthapent Kyron Laboratories  
Johannesburg, South Africa  
- 
Ethyl Alcohol (C2H5OH) Illovo Sugar Ltd. 
Durban, South Africa 
500 
Formaldehyde (35-40%) Radchem,  




Sigma-Aldrich® Chemie GmbH 
Steinheim, Germany 
F0507 
Glacial acetic acid  
(CH3COOH) 
Radchem 
Brackendowns, South Africa 
A1034X 
Haematoxylin Saarchem 
Merck Chemicals (Pty) Ltd  
Gauteng, South Africa 
SAAR2822000CB 
Halothane  Safeline Pharmaceuticals (Pty) Ltd. 
Johannesburg, South Africa 
- 


















Product Producer Product No. 
Hepes Buffer 100mM Sigma-Aldrich® Chemie GmbH 
Steinheim, Germany 
H-4034 
Hydrochloric acid (HCl) BDH 
Poole, England 
103076P 
Hydrogen peroxide (H2O2) Sigma-Aldrich
® Chemie GmbH 
Steinheim, Germany 
216763 
Isofor (Isoflurane)  
250ml 
Safeline Pharmaceuticals (Pty) Ltd. 
Johannesburg, South Africa 
_ 
JB-4  
Embedding solution A 
Polysciences, Inc. 
Warrington, PA, USA 
0226A 
JB-4 
Embedding solution B 
Polysciences, Inc. 
Warrington, PA, USA 
0226B 
JB-4 Catalyst  Polysciences, Inc. 
Warrington, PA, USA 
02618 
Lead II acetate trihydrate  Sigma-Aldrich® Chemie GmbH 
Steinheim, Germany 
316512 
Leibovitz medium Sigma-Aldrich® Chemie GmbH 
Steinheim, Germany 
L4386 
Light Green SF Yellowish  Sigma-Aldrich® Chemie GmbH 
Steinheim, Germany 
L1886 
Liquid nitrogen  Air Liquide  
South Africa 
_ 
Marking Dye for Tissue  Polysciences, Inc.  





MDA-kb2 American Type Culture Collection 










GenScript USA, Inc. 





















Cambridge, MA, USA 
ab21595 
Nitric acid (HNO3)  
(AR 67%) 
Sigam-Aldrich ® Chemie GmbH 
Steinheim, Germany 
38270 
OCT Medium  Medite 
Burgdorf, Germany 
_ 
ONE-Glo Luciferase  
Assay System  
Promega 




Sigam-Aldrich ® Chemie GmbH 
Steinheim, Germany 
158127 
Phloxine B  Merck KGaA                            
Darmstadt, Germany 
115926 
Phosphomolybdic acid  
hydrate 
Sigma-Aldrich® Chemie GmbH 
Steinheim, Germany 
P7390 
Picric acid solution  
(saturated aqueous) 





The Shearwater Group Inc. 










Winston Salem, NC, USA 
PSB-441 
Potassium chloride (KCl) Saarchem  
Merck Chemicals (Pty) Ltd  
Gauteng, South Africa 
SAAR5042020EM 
Potassium hydroxide  
(KOH) 
Sigma-Aldrich® Chemie GmbH 
Steinheim, Germany 
P5958 
Povidone Iodine Solution  
(10%) 
Dismed Pharma (Pty) Ltd. 
Gauteng, South Africa 
_ 
Proteinase K  Dako Denmark A/S 
Glostrup, Denmark 
S3020 


















Product Producer Product No. 
Sodium chloride  
0.9% 1000ml 
Adcock Ingram Critical Care 
Johannesburg, South Africa 
AFB 1324 
Sodium hydride (NaH) 
 
Sigma-Aldrich® Chemie GmbH 
Steinheim, Germany 
71620 
Sodium hydroxide (NaOH) Sigma-Aldrich® Chemie GmbH 
Steinheim, Germany 
S8045 
Sodium iodate (NaIO3) Merck KGaA                            
Darmstadt, Germany 
106525 
Sodium phosphate  
dibasic dodecahydrate  
(Na2HPO4.12H2O) 
Sigma-Aldrich® Chemie GmbH 
Steinheim, Germany 
71649 
Sodium phosphate  
monobasic monohydrate 
(NaH2PO4.1H2O) 















Sigma-Aldrich® Chemie GmbH 
Steinheim, Germany 
471283 
Tris base (Tris  
hydroxymethyl amino  
methane) 
Merck KGaA                            
Darmstadt, Germany 
1.08382.0500 




Mounting Medium with  
DAPI 
Vector Laboratories, Inc. 
Burlingame, CA, USA 
H-1200 
Xylene Saarchem  
Merck Chemicals (Pty) Ltd  


















Table 12 : Equipment 
Product Producer Product No. 
Accu-Edge® Disposable  
Microtome Blades 
Sakura Finetek USA, Inc. 
Torrance, CA, USA 
4689 
ACUSON Sequoia 512 Siemens AG 
Erlangen, Germany 
_ 
Alcohol Prep Pads  
Kendall WEBCOL 
Tyco Healthcare (Pty) Ltd. 
Gauteng, South Africa 
16818 
Alm Retractor – 4cm  
Spread 5.5mm Teeth 






Johannesburg, South Africa 
_ 
Axel Johnson  
Lab System HP-3 
Kunz Instruments AB 
Nynäshamn, Sweden 
205100 
Baby-Mixter Haemostat –  
Curved 14cm 
Fine Science Tools Inc. 
Heidelberg, Germany 
13013-14 
BD Micro-Fine + Demi 
 
BD Becton Dickinson 
Franklin Lakes, NJ, USA 
320829 
Cages  Tecniplast 
Buguggiate, Italy 
Type III H: 1291H  
Type IV: 1354G 
Carbon Steel Blades 
Size 23 
Surgical Blades CE 
South Africa 
0197 
Castroviejo Needle  
Holder – w/Lock  
Tungsten Carbide 14cm 
Fine Science Tools Inc. 
Heidelberg, Germany 
12565-14 
Catheter, 16G (57mm) 
Introcan 
B. Braun Melsungen AG 
Melsungen, Germany 
4252160B 
CO2 absorber  
Omnicon f/air 
A.M. Bickford, Inc. 
Wales Center, NY, USA 
80120 
Cotton Swabs  Hallowell EMC 
Pittsfield, MA, USA  
210A3832A 



















Product Producer Product No. 
Deltaphase® Operating  
Board and 2 pads 
Braintree Scientific, Inc. 

















Embedding Stubs Taab, Ltd. 
Aldermaston, UK 
E081 





Falcon tubes (50ml) BD Biosciences  





Cape Town, South Africa 
AM7508 
Gemini NX 
5u, C18, 110A, 50 x 2mm 
Phenomenex 
Torrance, CA, USA 
_ 
Glass knife 
406mm x 25mm x 8mm 
Agar Scientific Ltd. 
Stansted, UK 
G3516 
Gloves, sterile sempermed 
Vienna, Austria 
8260 54620 
Graefe Forceps - 0.8mm  
Tips Straight 
Fine Science Tools Inc. 
Heidelberg, Germany 
11050-10 
Graefe Forceps - 0.8mm  
Tips Slight Curve 
Fine Science Tools Inc. 
Heidelberg, Germany 
11051-10 
Harvard Small Animal  
Ventilator Model 683  
Harvard Apparatus 
Holliston, MA, USA 
550000 
Hot bead sterilizer  
Steri 250 




Incisor Loop Hallowell EMC 

















Product Producer Product No. 
Incubator Heraeus  
Hanau, Germany 
_ 
Induction chamber Stoelting Co. 




Royal Philips Electronics 





B. Braun Melsungen AG 
Melsungen, Germany 
4606108V 
Metzenbaum Scissors –  
Curved 14.5cm 
Fine Science Tools Inc. 
Heidelberg, Germany 
14017-14 
Microm Tissue  





Microscope cover  
glasses 22x40mm 
Marienfeld GmbH & Co.KG 
Lauda-Königshofen, Germany 
01 011 22 
Microscope glass slides 
76x26x1mm 
Marienfeld GmbH & Co.KG 
Lauda-Königshofen, Germany 
08 100 00 and 
10 016 12  
Mirror for Intubation  
Verification 
Hallowell EMC 
Pittsfield, MA, USA  
200A3683 
Nikon Digital Camera 






Nikon Instruments Inc. 
Melville, NY, USA 
_ 
Omnican® 100       
 
B. Braun Melsungen AG 
Melsungen, Germany 
9151141S 
Otoscope, Welch Allyn  
Li-Ion with operation  
Head 
Hallowell EMC 





Middleton, WI, USA 
_ 
Rat and Mice Feed 16% Afresh Vention (Pty) Ltd 
Durbanville, South Africa 
_ 
Rat ET Tube Introducer Hallowell EMC 





















Pittsfield, MA, USA  
200A3588 
Rodent Anesthesia Circuit  
Mask 
Harvard Apparatus 
Holliston, MA, USA 
723026 












Simpleware  Simpleware Ltd. 
Exeter, UK 
_ 
Spring Scissors 8mm Fine Science Tools Inc. 
Heidelberg, Germany 
15025-10 
Student Adson Forceps 
  
Fine Science Tools Inc. 
Heidelberg, Germany 
91106-12 
Student Adson Tissue  
Forceps – 1x2 Teeth 




23G x 1¼”  
Terumo Medical Corporation 
Tokyo, Japan 
_ 
Tilting WorkStand,  
Rodent 
Hallowell EMC 
Pittsfield, MA, USA  
000A3467   
Tissue Floating Bath  
TFB 45 
MEDITE® GmbH  
Burgdorf, Germany 
_ 






























Product Producer Product No. 
Vaporizer Modell 100 SurgiVet 
Wankesha, WI, USA 
V720100 
Veritas Microplate  
Luminometer 
Turner Biosystems _ 
VIS - Visiopharm 





Vortex Genie® 2 
 
Scientific Industries, Inc. 
Bohemia, NY, USA 
SI-0256 
X-Cite® 120 
Fluorescence Illumination  
System 




XSeries II ICP-MS  
 
Thermo Fisher Scientific _ 
2-0 Ethibond Excel  
Polyester Suture 
Johnson & Johnson (Pty) Ltd 
Midrand, South Africa 
X937  
4-0 Mersilk  
Non-absorbable silk 
Johnson & Johnson (Ptd) Ltd 
Brussels, Belgium 
W505 
6-0 Ethicon Prolene™  
Polypropylene Sutures  
Ethicon Inc. 
Somerville, NJ, USA 
M8706 
96-well Cell Culture Plate 
 
Nunc A/S 
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